Abstract
The accompanying chapters in this volume attest to the growth and complexity of catecholamine studies in recent years and provide some pointer to the correspondingly large literature associated with this field of research. Running parallel to these fundamental contributions and associated with what is probably an even larger number of publications, is that area of “applied” catecholamine study dealing with the clinical implications of this knowledge (Franzen and Eysell, Thus there has been vast research effort concerning the role of monoamines in psychiatric disease, particularly in the pathogenesis of depressive illness (e. g. Cole and Wittenborn, 1966) and of schizophrenia (e.g. Smythies, 1963) and the drugs which have been used to treat them (e. g. Clark and Del Giudice, the tumours secreting catecholamines, phaeochromocytoma and neuroblastoma-ganglioneuroma, have provided much information on amine disposition (e. g. Sandler and Ruthven, 1972); the genetically determined diseases such as familial dysautonomia (e. g. Gitlow et al., 1970), phenylketonuria (e. g. Lyman, 1963) and tyrosinosis (e. g. Gjessing, 1966) have overtones relating to catecholamine metabolism as does the study of such disparate clinical problems as essential hypertension (e. g. Mendlowitz et al., 1970) and morphine addiction (e. g. Gunne, 1963). Above all, it is in the study of Parkinson’s disease (Calne, 1970; Barbeau and Mcdowell, 1970) that “biochemical investment” has yielded the most handsome “clinical dividend” (Udenfriend, 1969). To attempt to evaluate each of these topics exhaustively would occupy considerably more space than is available to the writer in this volume. It has therefore seemed most valuable to tackle in depth a single topic, parkinsonism, and its relationship to the major and minor pathways of catecholamine biosynthesis and metabolism, whilst not omitting to point out, where relevant, the implications of this knowledge in the study of other disorders of monoamine metabolism.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Abrams, W.B., Solomon, H.M.: The human platelet as a pharmacologic model for theadrenergic neuron. Clin. Pharmacol. Ther. 10, 702–709 (1969).
Alm, P., Ehinger, B., Falck, B.: Histochemical studies on the metabolism of L-DOPA and some related substances in the exocrine pancreas. Acta physiol. scand. 76, 106–120 (1969).
Anagnoste, B., Goldstein, M.: The metabolism of tyramine-H3 in different regions of theCNS. Life Sci. 6, 1535–1540 (1967).
Andén, N.E., Butcher, S.G., Corrodi, H., Fuxe, K., Ungerstedt, U.: Receptor activity and turnover of dopamine and noradrenaline after neuroleptics. Europ. J. Pharmacol. 11, 303–314 (1970a).
Andén, N.E., Engel, J.: Central dopamine and noradrenaline receptor activity of the amines formedfrom m-tyrosine, α-methylra-tyrosine and α-methyldopa. J. Pharm. Pharmacol. 22, 548–550 (1970b).
Andén, N.E., Fuxe, K.: Protection of the neostriatal dopamine stores against reserpine by localtreatment with metatyramine. Acta pharmacol. (Kbh.) 28, 39–48 (1970c).
Andén, N.E., Carlsson, A., Dahlstrom, A., Fuxe, K., Hillarp, N.-A., Larsson, K.: Demonstration and mapping out of nigro-neostriatal dopamine neurons. Life Sci. 3, 523–530 (1964a).
Andén, N.E., Kerstell, J., Magnusson, T., Olsson, R., Roos, B.E., Steen, B., Steg, G., Svan-Borg, A., Thieme, G., Werdinius, B.: Oral L-dopa treatment of parkinsonism. Acta med. scand. 187, 247–255 (1970d).
Andén, N.E., Roos, B.-E., Werdinius, B.: On the occurrence of homovanillic acid and 3-methoxy–4-hydroxymandelic acid in human cerebrospinal fluid. Experientia (Basel) 19, 359–360 (1963a).
Andén, N.E.: Effects Of Chlorpromazine, Haloperidol And Reserpine On The Levels Of Phenolic Acidsin Rabbit Corpus Striatum. Life Sci. 3, 149–158 (1964B).
Anderson, P.J., D’Iorio, A.: Purification and properties of catechol-O-methyltransferase.Biochem. Pharmacol. 17, 1943–1949 (1968).
Andrews, R.S., Pridham, J.B.: Melanins from DOPA-containing plants. Phytochemistry 6, 13–18 (1967).
Anlyan, W.G., Hargrove, M.D., Jr., Ruffin, J.M., Wallace, D.K., Weaver, W.T., Kirshner, N.: Metastasizing bronchial adenoma. Occurrence in patient with the functioning carcinoid syndrome. J. Amer. med. Ass. 174, 415–417 (1960).
Ansel, R.D., Markham, C.H.: Effects of L-dopa in normal humans. In: L-Dopa and Parkinsonism, pp. 69–72, edit. A. Barbeau And F.H. Mcdowell. Philadelphia: Davis 1970.
Anton, A.H., Greer, M., Sayre, D.F., Williams, C.M.: Dihydroxyphenylalanine secretionin a malignant pheochromocytoma. Amer. J. Med. 42, 469–475 (1967).
Antunes, J.L., Macedo, C., Damasio, A.R.: Levodopa and migraine Lancet ii, 928 (1970).
Arakawa, T., Wad A, Y., Tad A, K., Ito, H.: Hyperpigmentation of the skin with DOPA-uria of a newborn. (A peculiar sign of an infant born of a thyrotoxic mother treated with methimazole.) Tohoku J. exp. Med. 80, 329–337 (1963).
Armstrong, M.D., Mcmillan, A., Shaw, K.N.F.: 3-Methoxy–4-hydroxy-D-mandelic acid, a urinary metabolite of norepinephrine. Biochim. biophys. Acta (Amst.) 25, 422–423 (1957).
Asatoor, A.M., Chamberlain, M.J., Emmerson, B.T., Johnson, J.R., Levi, A. J., Milne,M.D.: Metabolic effects of oral neomycin. Clin. Sci. 33, 111–124 (1967).
Axelrod, J.: Metabolism of epinephrine and other sympathomimetic amines. Physiol. Rev. 39, 751–776 (1959).
Axelrod, J.: Methylation reactions in the formation and metabolism of catecholamines and other biogenic amines. Pharmacol. Rev. 18, 95–113 (1966).
Axelrod, J.: Discussion on paper of CHASE, T.N.: Neurology 20, 130 (1970).
Axelrod, J., Tomchick, R.: Enzymatic 0-methylation of epinephrine and other catechols. J. biol. Chem. 233, 702–705 (1958).
Barbeau, A.: Biochemistry of Parkinson’s disease. Proc. 7th int. Congr. Neurol., Rome, Vol. 2, Societa Grafica Romana, Rome, p. 925 (1961).
Barbeau, A.: The pathogenesis of Parkinson’s disease: a new hypothesis. Canad. med. Ass. J. 87, 802–807 (1962).
Barbeau, A.: Parkinson’s disease as a systemic disorder. In: Third Symposium on Parkinson’s Disease, pp. 66–73, edit. F.J. Gillingham And I.M.L. Donaldson. Edinburgh: Livingstone 1969a.
Barbeau, A.: L-dopa therapy in Parkinson’s disease: a critical review of nine years experience. Canad. med. Ass. J. 101, 791–800 (1969b).
Barbeau, A.: Rationale for the use of L-dopa in the torsion dystonias. Neurology 20, 96–102 (1970a).
Barbeau, A.: Functions of the striatum. A new proposal based on experience with L-DOPA in extra-pyramidal disorders. Proc. 4th Bel-Air Symposium, Geneva (1970b) (in the press).
Barbeau, A., De Groot, J. A., Joly, J.G., Raymond-Tremblay, D., Donaldson, J.: Urinary excretion of a 3–4, dimethoxyphenylethylamine-like substance in Parkinson’s disease. Rev. canad. Biol. 22, 469–472 (1963).
Barbeau, A., Friesen, H.: Treatment of Wilson’s disease with L-dopa after failure with penicillamine Lancet i, 1180–1181 (1970).
Barbeau, A., Gillo-Joffroy, L., Boucher, R., Nowaczynski, W., Genest, J.: Renin-aldosterone system in Parkinson’s disease. Science 165, 291–292 (1969).
Barbeau, A., Jasmin, G.: Dosage de l’acide 5-hydroxyindoleacétique urinaire dans la maladie de Parkinson. Rev. canad. Biol. 20, 837–838 (1961).
Barbeau, A., Mcdowell, F.H. Edit: L-Dopa and Parkinsonism, pp. 1–433. Philadelphia: Davis 1970.
Barbeau, A., Murphy, G.F., Sourkes, T.L.: Excretion of dopamine in diseases of the basal ganglia. Science 133, 1706–1707 (1961).
Barbeau, A., Singh, P., Gaudreau, P., Joubert, M.: Effect of 3,4-dimethoxyphenylethylamine in-jections on the concentration of catecholamines in the rat brain. Rev. canad. Biol. 24, 229–232 (1965).
Barbeau, A., Sourkes, T.L., Murphy,G.F.: Les catécholamines dans la maladie de Parkinson. In: Monoamines et système nerveux central, pp. 247–262, edit. J. De Ajuriaguerra. Genève: Georg 1962.
Barbeau, A., Trombitas, S.: The metabolism of tritium labelled dopamine in parkinsonian patients. In: Progress in Neurogenetics, pp. 352–356, edit. A. Barbeau And J.-R. Brunette, Int. Congr. Series 175. Amsterdam: Excerpta Med. Fndn. 1969.
Barger, G., Dale, H.H.: Chemical structure and sympathomimetic action of amines. J. Physiol. (Lond.) 41, 19–59 (1910).
Barolin, G.S., Bernheimer, H., Hornykiewicz, O.: Seitenverschiedenes Verhalten des Dopamins (3-Hydroxytyramin) in Gehirn eines Falles von Hemiparkinsonismus. Schweiz. Arch. Neurol. Neurochir. Psychiat. 94, 241–248 (1964).
Barolin, G.S., Hornykiewicz, O.: Zur diagnostischen Wertigkeit der Homo vanillinsäure im Liquor cerebrospinalis. Wien. klin. Wschr. 79, 815–818 (1967).
Bartholini, G., Da Prada, M., Pletscher, A.: Decrease of cerebral 5-hydroxytryptamine by 3,4-dihydroxyphenylalanine after inhibition of extracerebral decarboxylase. J. Pharm. Pharmacol. 20, 228–229 (1968).
Bartholini, G., Gey, K.F., Pletscher, A.: Enhancement of tyrosine transamination in vivo by cate-cholamines. Experientia (Basel) 26, 980–981 (1970a).
Bartholini, G., Kuruma, I., Pletscher, A.: Distribution and metabolism of L–3-0-methyldopa in rats. Brit. J. Pharmacol. 40, 461–467 (1970b).
Bartholini, G., Pletscher, A.: Cerebral accumulation and metabolism of C14-dopa after selective inhibition of peripheral decarboxylase. J. Pharmacol, exp. Ther. 161, 14–20 (1968).
Bartholini, G., Pletscher, A.: Effect of various decarboxylase inhibitors on the cerebral metabolism of dihydroxy-phenylalanine. J. Pharm. Pharmacol. 21, 323–324 (1969).
Bartholini, G., Kuruma, I.: New approaches for enhancing the dopamine content in the basal ganglia.Proc. 4th Bel-Air Symposium, Geneva, 1970 (In the press).
Battista, A. F., Goldstein, M., Nakatani, S., Anagnoste, B.: The effects of ventrolateral thalamic lesions on tremor and the biosynthesis of dopamine in monkeys with lesions in the ventromedial tegmentum. J. Neurosurg. 31, 164–171 (1969).
Bedard, P., Larochelle, L., Parent, A., Poirier, L.J.: The nigrostriatal pathway: a correlative study based on neuroanatomical and neurochemical criteria in the cat and the monkey. Exp. Neurol. 25, 365–377 (1969).
Bedard, P., Poirier, L. J., Sourkes, T.L.: Reversible effect of L-DOPA on tremor and catatoniainduced by α-methyl-β-tyrosine. Canad. J. Physiol. Pharmacol. 48, 82–84 (1970).
Behringer, K., Wilmanns, K.: Zur Harmin-Banisterin-Frage. Dtsch. med. Wschr. 55, 2081–2086 (1929).
Bernheimer, H.: Distribution of homovanillic acid in the human brain. Nature (Lond.) 204, 587–588 (1964).
Bernheimer, H.: Distribution of homovanillic acid in the human brain. Nature (Lond.) 204, BIRKMAYER, W., HORNYKIEWICZ, O.: Verteilung des 5-Hydroxytryptamins (Serotonin) im Gehirn des Menschen und sein Verhalten bei Patienten mit Parkinsonsyndrom. Klin. Wschr. 39, 1056–1059 (1961).
Bernheimer, H., Birkmayer, W., Hornykiewicz, O.: Zur Biochemie des Parkinson-Syn-droms des Menschen. Einfluß der Monoaminoxydase-Hemmer-Therapie auf die Konzentration des Dopamins, Noradrenalins und 5-Hydroxytryptamins im Gehirn. Klin. Wschr. 41, 465–469 (1963).
Bernheimer, H., Birkmayer, W., Hornykiewicz, O.: Homovanillinsäure im liquor cerebrospinalis: Untersuchungen beim Parkinson-Syndrom und anderen Erkrankungen des ZNS. Klin. Wschr. 78, 417–419 (1966).
Bernheimer, H., Jellinger, K., Seitelberger, F.: Zur Differenzierung des Parkinson-Syndroms:Biochemisch-neurohistologische Vergleichsuntersuchungen. Proc. 8th int. Congr. Neurol., Vienna, Vol. 4, Pt. I, Wiener medizinischen Akademie, Wien, 1965, pp. 145–148. Paper presented at the 9th International Congress of Neurology, New York,1969.
Bernheimer, H., Hornykiewicz, O.: Das Verhalten einiger Enzyme im Gehirn normaler und Parkinsonkranker Menschen. Arch. exp. Pathol. Pharmakol. 243, 295 (1962).
Bernheimer, H., Hornykiewicz, O.: Monoaminoxydase-Hemmer und Dopamin-, Noradrenalin-und 5-Hydroxytryptamin-Stoffwechsel im Gehirn Parkinson-kranker Menschen. Arch. exp. Pathol. Pharmakol. 245, 52 (1963).
Bernheimer, H., Hornykiewicz, O.: Das Verhalten des Dopamin-Metaboliten Homovanillinsäure im Gehirn von normalenund Parkinson-kranken Menschen. Arch. exp. Pathol. Pharmakol. 247, 305–306 (1964).
Bernheimer, H., Hornykiewicz, O.: Wirkung von Phenothiazinderivaten auf den Dopamin-(= 3-Hydroxytyramin)Stoffwechsel im Nucleus caudatus. Arch. exp. Pathol. Pharmakol. 251, 135–136 (1965a).
Bernheimer, H., Hornykiewicz, O.: Herabgesetzte Konzentration der Homovanillinsäure im Gehirn von Parkinson-krankenMenschen als Ausdruck der Störung des zentralen Dopaminstoffwechsels. Klin. Wschr. 43, 711–715 (1965b).
Bernheimer, H., Hornykiewicz, O.: Dopaminumsatz im Gehirn von normalen und parkinsonkranken Menschen. Wien. Z.Nervenheilk. 23, 110–114 (1966).
Bertler, A., Falck, B., Owman, C., Kosengren, E.: The localization of monoaminergic blood-brain barrier mechanisms. Pharmacol. Rev. 18, 369–385 (1966).
Bettag, W., Holbach, K.H.: Effect of L-dopa on different symptoms of Parkinson’s disease. In: Third Symposium on Parkinson’s Disease, pp. 181–184, edit. F.J. Gillingham And I.M.L. Donaldson. Edinburgh: Livingstone 1969.
Birkmayer, W.: Der α-Methyl-P-Tyrosin-Effekt bei extrapyramidalen Erkrankungen. Wien, klin. Wschr. 81, 10–12 (1969a).
Birkmayer, W.: Experimentelle Ergebnisse über die Kombinationsbehandlung des Parkinson-syndroms mit L-DOPA und einen Decarboxylasehemmer (Ro 4–4602). Wien. klin. Wschr. 81, 677–679 (1969b).
Birkmayer, W.: Failures in L-dopa therapy. In: L-Dopa and Parkinsonism, pp. 12–16, edit. A. Barbeau And F.H. Mcdowell. Philadelphia: Davis 1970a.
Birkmayer, W., Hornykiewicz, O.: Der L–3,4-Dioxyphenylalanin (= DOPA)-Effekt bei der Parkinson-Akinese. Wien. klin. Wschr. 73, 787–788 (1961).
Birkmayer, W., Hornykiewicz, O.: Der L-Dioxyphenylalanin (= DOPA)-Effekt beim Parkinson-Syndrom des Menschen:Zur Pathogenese und Behandlung der Parkinson-Akinese. Arch. Psychiat. Nervenkr. 203, 560–574 (1962).
Birkmayer, W., Hornykiewicz, O.: Weitere experimentelle Untersuchungen über L-DOPA beim Parkinson-Syndrom undReserpin-Parkinsonismus. Arch. Psychiat. Nervenkr. 206, 367–381 (1964).
Bischoff, F., Torres, A.: Determination of urine dopamine. Clin. Chem. 8, 370–377 (1962).
Björklund, A., Cegrell, L.: Unpublished work quoted in: Björklund, A., Cegrell, L., Falck, B. and Ritzen, M. Dopamine-containing cells in sympathetic ganglia. Acta physiol. scand. 78, 334–338 (1970).
Blaschko, H.: The specific action of β-DOPA decarboxylase. J. Physiol. (Lond.) 96, 50P–51P (1939).
Blaschko, H.: Substrate specificity of amino-acid decarboxylases. Biochim. biophys. Acta (Amst.) 4, 130–137 (1950).
Blaschko, H.: Metabolism and storage of biogenic amines. Experientia (Basel) 13, 9–12 (1957).
Blaschko, H.: The development of current concepts of catecholamine formation. Pharmacol. Rev. 11, 307–316 (1959).
Blaschko, H., Burn, J.H., Langemann, H.: The formation of noradrenaline from dihydroxyphenyl-serine. Brit. J. Pharmacol. 5, 431–437 (1950).
Blaschko, H., Chrusciel, T.L.: The decarboxylation of amino acids related to tyrosine and their awakening action in reserpine-treated mice. J. Physiol. (Lond.) 151, 272–284 (1960).
Blaschko, H., Holton, P., Sloane Stanley, G.H.: Enzymic formation of pressor amines. J. Physiol. (Lond.) 108, 427–439 (1949).
Bonham Carter, S., Hunter, K.R., Laurence, D.R., Sandler, M., Stern, G.M., Youdim, M.B.H.: In preparation (1971).
Bonham Carter, S., Karoum, F., Sandler, M., Youdim, M.B.H.: The effect of tyramine on phenolic acid and alcohol excretion in man. Brit. J. Pharmacol. 39, 202P–203P (1970).
Booth, A.N., Williams, R.T.: Dehydroxylation of catechol acids by intestinal contents. Biochem. J. 88, 66P–67P (1963a).
Booth, A.N., Williams, R.T.: Dehydroxylation of caffeic acid by rat and rabbit caecal contents and sheep rumenliquor. Nature (Lond.) 198, 684–685 (1963b).
Boudin, G., Castaigne, P., Lhermitte, F., Beck, H., Guillard, A., Marteatt, R., Pepin, B., Roudot, P., Raphy, B.: Traitement des syndromes parkinsoniens par la L-dopa. A propos de 77 observations. Rev. Neurol. 122, 89–102 (1970).
Boijllin, D.J., O’Brien, R.A.: Accumulation of dopamine by blood platelets from normal subjects and parkinsonian patients under treatment with L-DOPA. Brit. J. Pharmacol. 39, 779–788 (1970).
Boulton, A. A., Pollitt, R.J., Majer, J.R.: Identity of a urinary ‘pink spot’ in schizo-phrenia and Parkinson’s disease. Nature (Lond.) 215, 132–134 (1967).
Boulton, A. A., Quan, L., Majer, J.R.: Urinary excretion and cerebral distribution of β-tyramine. In: L-dopa and Parkinsonism, pp. 227–231, edit. A. Barbeaij And F.H. Mcdowell. Philadelphia: Davis 1970.
Bowers, M.B., Jr., Heninger, G.R., Gerbode, F.: Cerebrospinal fluid 5-hydroxyindoleacetic acid and homovanillic acid in psychiatric patients. Int. J. Neuropharmacol. 8, 255–262 (1969).
Bozzi, R., Bruno, A., Allegranza, A.: Urinary metabolites of some monoamines and clinical effects under reserpine and chlorpromazine. Brit. J. Psychiat. Ill, 176–182 (1965).
Braham, J.: Adjuvants to L-dopa for Parkinsonism. Brit. med. J. 2, 540 (1970).
Braham, J., Sarova-Pinhas, I., Crispin, M., Golan, R., Levin, N., Szeinberg, A.: Oral phenylalanine and tyrosine tolerance tests in Parkinsonian patients. Brit. med. J. 2, 552–555 (1969).
Braham, J., Goldhammer, Y.: Apomorphine in Parkinsonian tremor. Brit. med. J. 3, 768 (1970).
Bricolo, A., Dalle Ore, G.: Prime esperienze nel trattamento con L-dopa degli comatose prolungati posttraumatici. Sist. nerv., Fasc. 2–3, 175–180 (1970).
Brody, J. A., Chase, T.N., Gordon, E.K.: Depressed monoamine catabolite levels in cere-brospinal fluid of patients with Parkinsonism dementia of Guam. New Engl. J. Med. 282, 947–950 (1970).
Bruck, H., Gerstenbrand, F., Grundig, E., Teuflmayr, R.: tlber Ergebnisse von Liquor-analysen beim Parkinson-Syndrom. Acta neuropath. (Berl.) 3, 638–644 (1964).
Bruno, A., Bruno, S. C.: Effects of L-DOPA on pharmacological Parkinsonism. Acta psychiat. scand. 42, 264–271 (1966).
Burkard, W.P., Gey, K.F., Pletscher, A.: A new inhibitor of decarboxylase of aromatic amino acids. Experientia (Basel) 18, 411–412 (1962).
Burn, J.H.: Hypotension caused by L-dopa. Brit. med. J. 1, 629 (1970).
Butcher, L.L., Butcher, S.G., Larsson, K.: Effects of apomorphine, (+)-amphetamine, and nialamide on tetrabenazine-induced suppression of sexual behaviour in the male rat. Europ. J. Pharmacol. 7, 283–288 (1969).
Butcher, L.L., Engel, J.: Behavioural and biochemical effects of L-DOPA after peripheral decarboxylase inhibition. Brain Res. 15, 233–242 (1969).
Calne, D.B.: Parkinsonism: physiology, pharmacology and treatment, pp. 1–136. London: Arnold 1970.
Calne, D.B., Brennan, J., Spiers, A.S.D., Stern, G.M.: Hypotension caused by L-dopa. Brit. med. J. 1, 474–475 (1970).
Calne, D.B., Karoum, F., Ruthven, C.R.J., Sandler, M.: The metabolism of orally administered L-DOPA in Parkinsonism. Brit. J. Pharmacol. 37, 57–68 (1969a).
Calne, D.B., Sandler, M.: L-Dopa and Parkinsonism. Nature (Lond.) 226, 21–24 (1970).
Calne, D.B., Spiers, A.S.D., Stern, G.M., Laurence, D.R., Armitage, P.: L-Dopa in idiopathic Parkinsonism. Lancet ii, 973–976 (1969b).
Calne, D.B., Stern, G.M., Laurence, D.R., Sharkey, J., Armitage, P.: L-dopa in postencephalitic Parkinsonism. Lancet i, 744–747 (1969b).
Cammarata, P.S., Cohen, P.P.: Scope of transamination reaction in animal tissues. J. biol. Chem. 187, 439–452 (1950).
Carlsson, A.: The occurrence distribution and physiological role of catecholamines in the nervous system. Pharmacol. Rev. 11, 490–493 (1959).
Carlsson, A.: Drugs which block the storage of 5-hydroxytryptamine and related amines. In: Handbuch der experimentellen Pharmakologie, Vol. 19, 5-Hydroxytryptamine and Related Indolealkylamines, pp. 529–592, edit. V. Erspamer. Berlin: Springer 1966.
Carlsson, A.: Biochemical implications of dopa-induced actions on the central nervous system, with particular reference to abnormal movements. In: L-dopa and Parkinsonism, pp. 205–213, edit. A. Barbeau And F.H. Mcdowell. Philadelphia: Davis 1970.
Carlsson, A., Lindqvist, M.: Metatyrosine as a tool for selective protection of catecholamine stores against reserpine. Europ. J. Pharmacol. 2, 187–192 (1967).
Celesia, G.G., Barr, A.N.: Psychosis and other psychiatric manifestations of levodopatherapy. Arch. Neurol. 23, 193–200 (1970).
Challacombe, D.N., Sandler, M., Southgate, J.: Decreased duodenal monoamine oxidaseactivity in coeliac disease. Arch. Dis. Childh. 46, 213–215 (1971).
Chase, T.N.: 5-Hydroxytryptophan in Parkinsonism. Lancet ii, 1029–1030 (1970).
Chase, T.N., Schnur, J. A., Gordon, E.K.: Cerebrospinal fluid monoamine catabolites in drug-induced extrapyramidial disorders. Neuropharmacology 9, 265–268 (1970).
Cherington, M.: Parkinsonism, L-dopa and mental depression. J. Amer. Geriat. Soc. 18, 513–516 (1970).
Christenson, J.G., Dairman, W., Udenfriend, S.: Preparation and properties of a homogenous aromatic L-amino acid decarboxylase from hog kidney. Arch. Biochem. Biophys. 141, 356–367 (1970).
Chrusciel, M.: Changes resembling lupus erythematosus after prolonged treatment with Ro–4–4602, a potent inhibitor of 5-HTP-decarboxylase in white rats. Europ. J. Pharmacol. 8, 192–199 (1969).
Clark, W.G., Del Giudice, J.: Principles of psychopharmacology, pp. 1–814. New York: Academic Press 1970.
Cohen, G., Collins, M.: Alkaloids from catecholamines in adrenal tissue: possible role inalcoholism. Science 167, 1749–1751 (1970).
Cole, J.O., Wittenborn, J.R. (Edit.): Pharmacology of depression, pp. 1–189. Springfield: Thomas 1966.
Coleman, M.P., Barnet, A.: L-Dopa reversal of muscular spasm, vomiting and insomnia in a patient with an atypical form of familial dystonia. Trans. Amer, neurol. Ass. 94, 91–93 (1969).
Collins, G.G.S., Pryse-Davies, J., Sandler, M., Southgate, J.: Effect of pretreatment with oestradiol, progesterone and DOPA on monoamine oxidase activity in the rat. Nature (Lond.) 226, 642–643 (1970a).
Collins, G.G.S., Sandler, M., Williams, E.D., Youdim, M.B.H.: Multiple forms of human brain mitochondrial monoamine oxidase. Nature (Lond.) 225, 817–820 (1970b).
Collins, G.G.S., West, G.B.: The release of 3-H-dopamine from the isolated rabbit ileum. Brit. J. Pharmacol. 34, 514–522 (1968).
Constantinidis, J., De La Torre, J.C., Tissot, R., Geissbuhler, F.: La barrière capillaire pour la dopa dans le cerveau et les différents organes. Psychopharmacologia (Beri.) 15, 75–87 (1969).
Contractor, S.F., Panigel, M., Sandler, M., Southgate, J.: In preparation (1971).
Cools, A.R., Van Rossum, J.M.: Caudal dopamine and stereotype behaviour of cats. Arch.int. Pharmacodyn. 187, 163–173 (1970).
Cooper, H.A., Gunn, J. A.: Harmalol in the treatment of parkinsonism. Lancet ii, 901–902 (1931).
Copps, S.G., Gerritsen, T., Smith, D.W., Waisman, H.A.: Urinary excretion of 3,4-dihydroxyphenylalanine (DOPA) in two children of short stature with malnutrition. J. Pediat. 62, 208–216 (1963).
Cotzias, G.C.: Manganese, melanins and the extrapyramidal system. J. Neurosurg. 24,170– 175 (1966).
Cotzias, G.C.: L-DOPA for Parkinsonism. New Engl. J. Med. 278, 630 (1968).
Cotzias, G.C.: 2-Amino–4-hydroxy–6,7-dimethyl-tetrahydropteridine in Parkinson’s disease. J. Amer, med. Ass. 210, 1594 (1969).
Cotzias, G.C., Mena, I., Papavasiliou, P.S.: Amelioration of the dystonia of chronic manganese poisoning by L-dopa. Neurology 19, 284–285 (1969a).
Cotzias, G.C., Papavasiliou, P.S.: Autoimmunity in patients treated with levodopa. J. Amer. med. Ass. 207, 1353 (1969a).
Gellene, R.: Modification of Parkinsonism: chronic treatment with L-dopa. NewEngl. J. Med. 280, 337–345 (1969b).
Gellene, R., Fehling, C., Kaufman, B., Mena, I.: Similarities between neurologic effects of L-dopaand of apomorphine. New Engl. J. Med. 282, 31–33 (1970).
Gellene, R., Aronson, R.B.: Parkinsonism and dopa. Trans. Ass. Amer. Phys. 81,171– 182 (1968).
Gellene, R., Van Woert, M.H., Sakamoto, A.: Melanogenesis and extrapyramidal diseases. Fed.Proc. 23, 713–718 (1964).
Gellene, R., Van Woert, M.H., Schiffer, L.M.: Aromatic amino acids and modification of Parkinsonism. New Engl. J. Med. 276, 374–379 (1967).
Coulson, W.F., Bender, D.A., Jepson, J.B.: Multiple electrophoresis peaks of rat liver decarboxylases for 3,4-dihydroxyphenylalanine and 5-hydroxytryptophan. Biochem. J. 115, 63P (1969).
Coulson, W.F., Henson, G., Jepson, J.B.: The production of M-tyrosine from L-phenylalanine by rat liver preparations. Biochim. biophys. Acta (Amst.) 156, 135–139 (1968).
Coyle, J.T., Snyder, S.H.: Antiparkinsonian drugs: inhibition of dopamine uptake in the corpus striatum as a possible mechanism of action. Science 166, 899–901 (1969).
Crawford, J.A., Burkhalter, A.: L-Aromatic amino acid decarboxylase of mouse kidney. Pharmacologist 12, 205 (1970).
Creveling, C.R., Dalgard, N., Shimizu, H., Daly, J.W.: Catechol O-methyltransferase. III. m-and β-0-methylation of catecholamines and their metabolites. Molec. Pharmacol. 6, 691–696 (1970).
Dacre, J.C., Scheline, R.R., Williams, R.T.: The role of the tissues and gutflora in the metabolism of [14C] homoprotocatechuic acid in the rat and rabbit. J. Pharm. Pharmacol. 20, 619–625 (1968).
Dacre, J.C., Williams, R.T.: The role of the tissues and gut microorganisms in the metabolism of [14C] protocatechuic acid in the rat. Aromatic dehydroxylation. J. Pharm. Pharmacol. 20, 610–618 (1968).
Dahlström, A., Fuxe, K.: Evidence for the existence of monoamine-containing neurons in the central nervous system. I. Demonstration of monoamines in the cell bodies of brain stem neurons. Acta physiol. scand. 62, Suppl. 232, pp. 1–55 (1964).
Dairman, W., Udenfriend, S.: The effect of L-dihydroxyphenylalanine administration on the level of adrenal tyrosine hydroxylase. Pharmacologist 12, 269 (1970).
Daly, J.W., Axelrod, J., Witkop, B.: Dynamic aspects of enzymatic 0-methylation and demethylation of catechols in vitro and in vivo. J. biol. Chem. 235, 1155–1159 (1960).
Daly, J.W., Benigni, J., Minnis, R., Kanaoka, Y., Witkop, B.: Synthesis and metabolism of 6-hydroxycatecholamines. Biochemistry 4, 2513–2525 (1965).
Damasio, A.R., Antunes, J.L., Macedo, C.: L-Dopa, parkinsonism and depression. Lancet ii, 611–612 (1970).
Daprada, M., Pletscher, A.: Acceleration of the cerebral dopamine turnover by chlorpromazine. Experientia (Basel) 22, 465–466 (1966).
Daprada, M., Pletscher, A.: Differential Uptake Of Biogenic Amines By Isolated 5-Hydroxytryptamine Organelles Ofblood Platelets. Life Sci. 8, 65–72 (1969).
Davis, V.E., Walsh, M.J., Yamanaka, Y.: Augmentation of alkaloid formation from do-pamine by alcohol and acetaldehyde in vitro. J. Pharmacol, exp. Ther. 174, 401–412 (1970).
Davison, A.N.: Physiological role of monoamine oxidase. Physiol. Rev. 38, 729–747 (1958).
Davison, A.N., Sandler, M.: Inhibition of 5-hydroxytryptophan decarboxylase by phenylalanine metabolites. Nature (Lond.) 181, 186–187 (1958).
Deeds, F., Booth, A.N., Jones, F.T.: Methylation and dehydroxylation of phenolic com-pounds by rats and rabbits. J. biol. Chem. 225, 615–621 (1957).
Degkwitz, R., Frowein, R., Kulenkampf, C., Mohs, V.: Über die Wirkungen des L-Dopa beim Menschen und deren Beeinflussung durch Reserpin, Chlorpromazin, Iproniazid und Vitamin B6. Klin. Wschr. 38, 120–123 (1960).
De La Torre, J. C.: Relative penetration of L-dopa and 5-HTP through the brain barrier using dimethyl sulfoxide. Experientia (Basel) 26, 1117–1118 (1970).
Dequattro, V.L., Sjoerdsma, A.: Origin of urinary tyramine and tryptamine. Clin. chim. Acta 16, 227–233 (1967).
Duvoisin, R.: Cholinergic–anticholinergic antagonism in parkinsonism. Arch. Neurol. 17, 124–136 (1967).
Duvoisin, R.C., Yahr, M.D., Cote, L.D.: Pyridoxine reversal of L-dopa effects in Parkin-sonism. Trans. Amer. neurol. Ass. 94, 81–82 (1969).
Ehringer, H., Hornykiewicz, O.: Verteilung von Noradrenalin und Dopamin (3-Hydroxy-tyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin. Wschr. 38, 1236–1239 (1960).
Epstein, D., Gunn, J.A., Virden, C.J.: The action of some amines related to adrenaline. I. Methoxyphenylethylamines. J. Physiol. (Lond.) 76, 224–246 (1932).
Ernst, A.M.: Phenomena of the hypokinetic rigid type caused by 0-methylation of dopamine in the para-position. Nature (Lond.) 193, 178–179 (1962).
Ernst, A.M.: Relation between the action of dopamine and apomorphine and their 0-methylated derivatives upon the CNS. Psychopharmacologia (Berl.) 7, 391–399 (1965).
Ernst, A.M.: The role of biogenic amines in the extra-pyramidal system. Acta physiol. pharmacol. neerl. 15, 141–154 (1969).
Everett, G.M., Borcherding, J.W.: L-Dopa: effect on concentrations of dopamine, norepinephrine and serotonin in brains of mice. Science 168, 849–850 (1970).
Evetts, K.D., Uretsky, N.J., Iversen, L.L., Iversen, S.D.: Effects of 6-hydroxydopamine on CNS catecholamines, spontaneous motor activity and amphetamine induced hyperactivity in rats. Nature (Lond.) 225, 961–962 (1970).
Faull, R.L.M., Laverty, R.: Changes in dopamine levels in the corpus striatum following lesions in the substantia nigra. Exp. Neurol. 23, 332–340 (1969).
Fehling, C.: Treatment of Parkinson’s syndrome with L-DOPA, a double blind study. Acta neurol. scand. 42, 367–372 (1966).
Fekete, M., Kurti, A.M.: On the dopaminergic nature of the gnawing compulsion induced by apomorphine in mice. J. Pharm. Pharmacol. 22, 377–379 (1970).
Fellman, J.H.: Inhibition of DOPA decarboxylase by aromatic acids associated with phenylpyruvic oligophrenia. Proc. Soc. exp. Biol. (N.Y.) 93, 413–414 (1956).
Ferrini, R., Glässer, A.: In vitro decarboxylation of new phenylalanine derivatives. Biochem. Pharmacol. 13, 798–801 (1964).
Fleming, P., Makar, H., Hunter, K.R.: Levodopa in drug-induced extrapyramidal disorders. Lancet ii, 1186 (1970).
Fonnum, F., Larsen, K.: Purification and properties of dihydroxyphenylalanine transaminase from guinea pig brain. J. Neurochem. 12, 589–598 (1965).
Fotino, S., Blaueox, M.D.: Renin activity and catecholamine excretion in Parkinsonism. Clin. Res. 18, 499 (1970).
Franzen, F., Eysell, K.: Biologically active amines found in man. Their biochemistry, pharmacology and pathophysiological importance, pp. 1–244. Oxford: Pergamon 1969.
Friedhoff, A. J., Van Winkle, E.: Isolation and characterization of a compound from the urine of schizophrenics. Nature (Lond.) 194, 897–898 (1962).
Funk, C.: Synthesis of dl–3: 4-dihydroxyphenylalanine. J. Chem. Soc. 99, 554–557 (1911).
Fuxe, K., Goldstein, M., Ljungdahl, A.: Antiparkinsonian drugs and central dopamine neurons. Life Sci. Pt. I 9, 811–824 (1970).
Fuxe, K., Hökfelt, T., Nilsson, O.: Factors involved in the control of the activity of the tuberoinfundibular dopamine neurons during pregnancy and lactation. Neuroendocrinology 5, 257–270 (1969).
Garland, H., Pearce, J.: Neurological complications of carbon monoxide poisoning. Quart. J. Med. 36, 445–455 (1967).
Gelinas, R., Pellerin, J., D’Iorio, A.: Biochemical observations of a chromaffine tumour. Rev. canad. Biol. 16, 445–450 (1957).
George, H., Gabay, S.: Brain aromatic aminotransferase. I. Purification and some properties of pig brain L-phenylalanine–2-oxoglutarate aminotransferase. Biochim. biophys. Acta (Amst.) 167, 555–566 (1968).
Gerstenbrand, F.: Failures of L-dopa treatment. In: L-Dopa and Parkinsonism, pp. 16–20, edit. A. Barbeau And F.H. Mcdowell. Philadelphia: Davis 1970.
Gerstenbrand, F., Gründig, E.: Amino acids after L-dopa. In: L-Dopa and Parkinsonism, pp. 246–249, edit. A. Barbeau And F.H. Mcdowell. Philadelphia: Davis 1970.
Gessa, G.L., Vargiu, L., Crabai, F., Boero, G.C., Caboni, F., Camba, R.: Selective increase of brain dopamine induced by gamma-hydroxybutyrate. Life Sci. 5, 1921–1930 (1966).
Gey, K.F.: 4-Hydroxyphenylpyruvat und 3,4-Dihydroxyphenylpyruvat als Noradrenalin-Vorstufen. Helv. physiol. Acta 23, C89 (1965).
Gey, K.F., Burkard, W.P., Pletscher, A.: Variation of the norepinephrine metabolism of the rat heart with age. Gerontologia (Basel) 11, 1–11 (1965).
Gey, K.F., Messiha, F.: Einfluß der DOPA-Transaminierung auf die DOPA-Decarboxylierung in vitro. Experientia (Basel) 20, 498–499 (1964).
Gibb, J.W., Webb, J.G.: The effects of reserpine, α-methyltyrosine, and L–3,4-dihydroxy-phenylalanine on brain tyrosine transaminase. Proc. nat. Acad. Sci. (Wash.) 63, 364–369 (1969).
Gitlow, S.E., Bertani, L.M., Wilk, E., Li, B.L., Dziedzic, S.: Excretion of catecholamine metabolites by children with familial dysautonomia. Pediatrics 46, 513–522 (1970).
Gjessing, L.R. (Edit.): Symposium on tyrosinosis, 1966, Universitetsforlaget, Oslo, pp. 1–132 (1966).
Gjessing, L.R. (Edit.): Biochemistry of functional neural crest tumors. Advanc. clin. Chem. 11, 82–131 (1968).
Godwin-Austen, R.B.,Frears,C.C., Bergmann, S., Parkes, J. D., Knill-Jones, R. P.: Combined treatment of Parkinsonism with L-dopa and amantadine. Lancet ii, 383–385 (1970).
Goldberg, L.I., Sonneville, P. F., Mcnay, J.L.: An investigation of the structural requirements for dopamine-like renal vasodilation: phenylethylamines and apomorphine. J. Pharmacol, exp. Ther. 163, 188–197 (1968).
Goldberg, L.I., Yeh, B.K.: Specific block of dopamine receptors in the renal vascular bed by chlorpromazine. Abstr. 4th int. Congr. Pharmacol. Basel, p. 359 (1969).
Golden, R.L., Mortati, F.S., Schroeter, G.A.: Levodopa, pyridoxine and burning feet. J. Amer. med. Ass. 213, 628 (1970).
Goldstein, M., Anagnoste, B., Owen, W.S., Battista, A.F.: The effects of ventromedial tegmental lesions on the biosynthesis of catecholamines in the striatum. Life Sci. 5, 2171–2176 (1966).
Goldstein, M., Anagnoste, B., Owen, W.S., Battista, A.F.: The effects of ventromedial tegmental lesions on the disposition of dopamine inthe caudate nucleus of the monkey. Brain Res. 4? 298–300 (1967).
Goldstein, M., Anagnoste, B., Yamamoto, A., Felch, W.C., Jr.: Regional distribution and metabolism of H3-tyramine in the rat brain. J. Pharmacol, exp. Ther. 171, 196–204 (1970a).
Goldstein, M., Battista, A. F., Nakatani, S., Anagnoste, B.: Drug-induced relief of the tremor in monkeys with mesencephalic lesions. Nature (Lond.) 224, 382–384 (1969e).
Goldstein, M., Battista, A. F., Nakatani, S., Anagnoste, B.: Drug-induced relief of experimental tremor in monkeys. Neurology 20, 89–95 (1970b).
Goldstein, M., Freedman, L.S., Backstrom, T.: The inhibition of catecholamine biosynthesis by apomorphine. J. Pharm. Pharmacol. 22, 715–717 (1970c).
Goldstein, M., Friedhoff, A.J., Pomerantz, S., Contrera, J.F.: The formation of 3,4-dihydroxy-phenylethanol and 3-methoxy–4-hydroxyphenylethanol from 3,4-dihydroxyphenyl-ethylamine in the rat. J. biol. Chem. 236, 1816–1821 (1961).
Goldstein, M., Fuxe, K., Battista, A. F., Backstrom, T., Nakatani, S.: The effects of antiparkinsonian drugs (AP) on striatal dopamine. Fed. Proc. 29, 680 (1970d).
Goodall, Mcc.: Dihydroxyphenylalanine and hydroxytyramine in mammalian suprarenals. Acta chem. scand. 4, 550 (1950).
Good All, Mcc., Alton, H.: Dopamine (3-hydroxytyramine) metabolism in parkinsonism. J. clin. Invest. 48, 2300–2308 (1969).
Good All, Mcc., Harlan, W.R., Jr., Alton, H.: Decreased noradrenaline (norepinephrine) synthesis in neurogenic orthostatic hypotension. Circulation 38, 592–603 (1968).
Goodwin, B.L.: In preparation (1971).
Goodwin, B.L., Karoum, F., Ruthven, C.R.J., Sandler, M.: In preparation (1971).
Goodwin, F.K., Brodie, H.K.H., Murphy, D.L., Bunney,W.E., Jr.: Administration of a peripheral decarboxylase inhibitor with L-dopa to depressed patients. Lancet i, 908–911 (1970a).
Goodwin, F.K., Brodie, H.K.H., Murphy, D.L., Bunney,W.E., Jr.: L-Dopa, catecholamines and behaviour: a clinical and biochemical study indepressed patients. Paper presented at Annual Meeting, Society of Biological Psychiatry, San Francisco, May 9th (1970b).
Gottfries, C.G., Gottfries, I., Roos, B.E.: Homovanillic acid and 5-hydroxyindoleacetic acid in the cerebrospinal fluid of patients with senile dementia, presenile dementia and parkinsonism. J. Neurochem. 16, 1341–1345 (1969).
Green, J.: The treatment of parkinsonism with L-dopa and amantadine. J. Fla. med. Ass. 57, 28–33 (1970).
Greer, M.: L-Dopa therapy in Parkinson’s disease. J. Fla. med. Ass. 57, 23–27 (1970).
Greer, M., Williams, C.M.: Dopamine metabolism in Parkinson’s disease. Neurology 13, 73–76 (1963).
Grelak, R.P., Clark, R., Stump, J.M., Vernier, V.G.: Amantadine, rimantadine, catecholamine release and parkinsonism. Pharmacologist 12, 235 (1970a).
Grelak, R.P., Clark, R., Stump, J.M., Vernier, V.G.: Amantadine-dopamine interaction: possible mode of action in Parkinsonism.Science 169, 203–204 (1970b).
Groppetti, A., Algeri, S., Bloom, F., Costa, E., Revuelta, A.: Central effects of intracisternal injections of 6-hydroxy dopamine (6-HDM). Pharmacologist 11, 275 (1969).
Guggenheim, M.: Dioxyphenylalanin, eine neue Aminosäure aus Vicia faba. Z. physiol. Chem. 88, 276–284 (1913).
Guldberg, H.C., Ashcroft, G.W., Crawford, T.B.B.: Concentrations of 5-hydroxyindolylacetic acid and homovanillic acid in the cerebrospinal fluid of the dog before and during treatment with probenecid. Life Sci. 5, 1571–1575 (1966).
Guldberg, H.C., Turner, J.W., Hanieh, A., Ashcroft, G.W., Crawford, T.B.B., Perry, W.L.M., Gillingham, F.J.: On the occurrence of homovanillic acid and 5-hydroxyindol–3-ylacetic acid in the ventricular CSF of patients suffering from Parkinsonism. Confin. neurol. (Basel) 29, 73–77 (1967).
Günne, L.: Catecholamines and 5-hydroxytryptamine in morphine tolerance and withdrawal. Acta physiol. scand. 58, Suppl. 204, pp. 1–91 (1963).
Günne, L.-M., Lidvall, H.-F.: The urinary output of catecholamines in narcolepsy under resting conditions and following administration of dopamine, dopa and dops. Scand. J. clin. Lab. Invest. 18, 425–430 (1966).
Haase, H.J., Janssen, P.A.J.: The action of neuroleptic drugs, pp. 1–174. Amsterdam: North-Holland 1965.HÄLLSTRÖM, T., PERSSON, T.: L-Dopa and non-emission of semen. Lancet i, 1231–1232 (1970).
Halushka, P.V., Hoffmann, P.C.: Does tetrahydropapaveroline contribute to the cardiovascular actions of dopamine ? Biochem. Pharmacol. 17, 1873–1880 (1968).
Hanig, J. F., Morrison, J.M., Jr., Krop, S.: Dimethyl sulfoxide (DMSO) and ethanol (EtOH) induced alteration in the permeability of the blood-brain barrier (BBB) to parenteral catecholamines in the neonate chick. Pharmacologist 12, 223 (1970).
Hanington, E.: Preliminary report on tyramine headache. Brit. med. J. 2, 550–551 (1967).
Hanington, E., Harper, A.M.: The role of tyramine in the aetiology of migraine and related studies on the cerebral and extracerebral circulations. Headache 78, 84–97 (1968).
Hanson, A., Von Studnitz, W.: Demonstration of urinary N-acetyldopamine in patients with neuroblastoma. Clin. chim. Acta 11, 384–385 (1965).
Hartman, W.J., Akawie, E.I., Clark, W.G.: Competitive inhibition of 3,4-dihydroxy-phenylalanine (DOPA) decarboxylase in vitro. J. biol. Chem. 216, 507–529 (1955).
Hassler, R.: Zur Pathologie der Paralysis agitans und des postenzephalitischen Parkinsonismus. J. Psychol. Neurol. (Lpz.) 48, 387–476 (1938).
Hassler, R., Riechert, T.: Indikationen und Lokalisations-Methode der gezielten Hirnoperation. Nervenarzt 25, 441–447 (1954).
Haverback, B.J., Dyce, B., Thomas, H.V.: Indole metabolism in the malabsorption syndrome. New Engl. J. Med. 262, 754–757 (1960).
Henning, M.: Studies on the mode of action of α-methyldopa. Acta physiol. scand. Suppl. 322, 1–37 (1969).
Henning, M., Rubenson, A.: Central hypotensive effect of L–3, 4-dihydroxyphenylalanine in the rat. J. Pharm. Pharmacol. 22, 553–560 (1970).
Hermann, H., Mornex, R.: Human tumours secreting catecholamines. Clinical and physiopathological study of the pheochromocytomas, pp. 1–207. Oxford: Pergamon 1964.
Hippixjs, H., Logemann, G.: Zur Wirkung von Dioxyphenylalanin (L-DOPA) auf extra-pyramidalmotorische Hyperkinesen nach langfristiger neuroleptischer Therapie. Arzneimittel-Forsch. 20, 894–896 (1970).
Hirschmann, J., Mayer, K.: Zur Beeinflussung der Akinese und anderer extrapyramidalmotorischer Störungen mit L-Dopa (L-Dihydroxyphenylalanin). Dtsch. med. Wschr. 89, 1877–1880 (1964).
Hofmann, W.W., Ryan, R.L.: A controlled study of L-DOPA in Parkinson’s disease. Calif. Med. 112, 9–14 (1970).
Holtz, P.: Introductory remarks. Pharmacol. Rev. 18, 85–88 (1966).
Holtz, P., Credner, K., Koepp, W.: Die enzymatische Entstehung von Oxytyramin im Organismus und die physiologische Bedeutung der Dopadecarboxylase. Arch. exp. Pathol. Pharmakol. 200, 356–388 (1942).
Holtz, P., Heise, R., Lüdke, K.: Fermentativer Abbau von L-Dioxyphenylalanin (Dopa) durch Niere. Arch. exp. Pathol. Pharmakol. 191, 87–118 (1938).
Holtz, P., Palm, D.: Pharmacological aspects of vitamin B6. Pharmacol. Rev. 16, 113–178 (1964).
Holtz, P., Stock, K., Westermann, E.: Pharmakologie des Tetrahydropapaverolins und seine Entstehung aus Dopamin. Arch. exp. Pathol. Pharmakol. 248, 387–405 (1964).
Holtz, P., Westermann, E.: Hemmung der Glutaminsäuredecarboxylase des Gehirns durch Brenzcatechinderivate. Arch. exp. Pathol. Pharmakol. 231, 311–332 (1957).
Holzer, G., Hornykiewicz, O.: Über den Dopamin-(Hydroxytyramin-) Stoffwechsel im Gehirn der Ratte. Arch. exp. Pathol. Pharmakol. 237, 27–33 (1959).
Honos, E., Ericsson, A.D., Mccann, D.S.: Parahydroxyphenylpyruvic acid excretion in parkinsonism. Life Sci. Part I, 9, 159–166 (1970).
Horn, A.S., Coyle, J.T., Snyder, S.H.: Inhibition of catecholamine (CA) uptake into rat brain synaptosomes by antiparkinsonian drugs: structure-activity relationships. Pharmacologist 12, 295 (1970).
Hornykiewicz, O.: Die topische Lokalisation und das Verhalten von Noradrenalin und Dopamin (3-Hydroxytyramin) in der Substantia nigra des normalen und Parkinsonkranken Menschen. Wien klin. Wschr. 75, 309–312 (1963).
Hornykiewicz, O.: Dopamine (3-hydroxytyramine) and brain function. Pharmacol. Rev. 18, 925–964 (1966).
Hornykiewicz, O.: How does L-dopa work in Parkinsonism? In: L-Dopa and Parkinsonism, pp. 393–399, edit. A. Barbeau And F.H. Mcdowell, Philadelphia: Davis 1970a.
Hornykiewicz, O.: Histochemistry, biochemistry and pharmacology of brain catecholamines in extrapyramidal syndromes in man. Proc. 4th Bel-Air Symposium, Geneva, 1970b. In the press.
Horwitz, D., Goldberg, L. I., Sjoerdsma, A.: Increased blood pressure responses to dopamine and norepinephrine produced by monoamine oxidase inhibitors in man. J. Lab. clin. Med. 56, 747–753 (1960).
Horwitz, D., Lovenberg, W., Engelman, K., Sjoerdsma, A.: Monoamine oxidase inhibitors, tyramine and cheese. J. Amer. med. Ass. 188, 1108–1110 (1964).
Hubert, J.W.A., Van Rossum, J.G.: An abortive form of Parkinson’s Disease? Psychiat. Neurol. Neurochir. (Amst.) 72, 525–531 (1969).
Hughes, R.C., Polgar, J.G., Weightman, D., Walton, J.N.: L-Dopa in Parkinsonism and the influence of previous thalamotomy. Brit. med. J. 1, 7–13 (1971).
Hunter, K.R., Boakes, A. J., Laurence, D.R., Stern, G.M.: Monoamine oxidase inhibitors and L-dopa. Brit. med. J. 3, 388 (1970a).
Hunter, K.R., Stern, G.M.: Personal communication (1971).
Hunter, K.R., Stern, G.M., Laurence, D.R.: Use of levodopa with other drugs. Lancet ii, 1283–1285 (1970b).
Hunter, K.R., Armitage, P.: Amantadine in parkinsonism. Lancet i, 1127–1129 (1970c).
Hunter, K.R.: Combined Treatment Of Parkinsonism With L-Dopa And Amantadine. Lancet Ii,566 (1970D).
Hunter, K.R., Sharkey, J.: Levodopa in postencephalitic parkinsonism. Lancet ii, 1366–1367(1970e).
Hyyppä, M., Rinne, U.K., Sonninen, V.: The activating effect of L-dopa treatment on sexual functions and its experimental background. Acta neurol. scand. 46, Suppl. 43, 223 (1970).
Ingvarsson, C.G.: Orientierende klinische Versuche zur Wirkung des Dioxyphenylalanins (1-Dopa) bei endogener Depression. Arzneimittel-Forsch. 15, 849–852 (1965a).
Ingvarsson, G.: L-Dopa och astmatisk bronkit. Nord. Med. 74, 1166–1167 (1965b).
Jameson, H.D.: Pyridoxine for levodopa-induced dystonia. J. Amer. med. Ass. 211, 1700 (1970).
Jenkins, R.: Laevo-dopa for parkinsonism. Brit. med. J. 2, 361–362 (1970).
Jenkins, R.B., Groh, R.H.: Psychic effects from levodopa. J. Amer. med. Ass. 212, 2265 (1970a)
Jenkins, R.B., Groh, R.H.: Mental symptoms in parkinsonian patients treated with L-dopa. Lancet ii, 177–180(1970b).
Jequier, E., Robinson, D.S., Lovenberg, W., Sjoerdsma, A.: Further studies on tryptophan hydroxylase in rat brainstem and beef pineal. Biochem. Pharmacol. 18, 1071–1081 (1969).
Johansson, B., Roos, B.-E.: 5-Hydroxyindoleacetic and homovanillic acid levels in the cerebrospinal fluid of healthy volunteeers and patients with Parkinson’s syndrome. Life Sci. 6, 1449–1454 (1967).
Johnston, J. P.: Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem. Pharmacol. 17, 1285–1297 (1968).
Jones, N.F., Walker, G., Ruthven, C.R.J., Sandler, M.: α-Methyl-p-tyrosine in the management of phaeochromocytoma. Lancet ii, 1105–1110 (1968).
Joyce, D.: Changes in the 5-hydroxytryptamine content of rat, rabbit and human brain after death. Brit. J. Pharmacol. 18, 370–380 (1962).
Kahler, H.J., Heilmeyer, L.: Klinik und Pathophysiologie des Karzinoids und Karzinoidsyndroms unter besonderer Berücksichtigung der Pharmakologie des 5-Hydroxy-tryptamins. Ergebn. inn. Med. Kinderheilk. 16, 292–559 (1961).
Kamberi, I.A., Mical, R.S., Porter, J.C.: Luteinizing hormone-releasing activity in hypophysial stalk blood and elevation by dopamine. Science 166, 388–390 (1969).
Karoum, F., Poliakoff, S., Ruthven, C.R.J., Sandler, M.: TO be published (1971).
Kaufman, S.: Coenzymes and hydroxylases: ascorbate and dopamine-β-hydroxylase; tetra-hydropteridines and phenylalanine and tyrosine hydroxylases. Pharmacol. Rev. 18, 61–69 (1966).
Key, B. J., Marley, E.: The effect of the sympathomimetic amines on behaviour and electrocortical activity of the chicken. Electroenceph. clin. Neurophysiol. 14, 90–105 (1962).
Kier, L.B., Truitt, E.B., Jr.: The preferred conformation of dopamine from molecular orbital theory. J. Pharmacol, exp. Ther. 174, 94–98 (1970).
Kirshner, N.: Pathway of noradrenaline formation from dopa. J. biol. Chem. 226, 821–825 (1957).
Klawans, H.L., Jr., Garvin, J.S., Shekelle, R.B.: The effect of previous antiparkinson surgery on L-dopa treatment. Presbyterian-St. Lukes Hosp. med. Bull. 8, 115–117 (1969).
Weiner, W.: L-Dopa and cerebrospinal fluid homovanillic acid in parkinsonism. Proc. 2nd int. Meeting int. Soc. Neurochem., Milan, p. 245 (1969).
Klerman, G.L., Schildkraut, J. J., Hasenbush, L.L.: Clinical experiences with dihydroxy-phenylalanine (dopa) in depression. J. psychiat. Res. 1, 289–297 (1963).
Knox, W.E.: Phenylketonuria. In: The Metabolic Basis of Inherited Disease, 2nd Edn., pp. 258–294, edit. J.B. Stanbury, J.B. Wyngaarden And D.S. Fredrickson. New York: McGraw-Hill 1966.
Koe, B.K., Weissman, A.: The pharmacology of para-chlorophenylalanine, a selective deple-tor of serotonin stores. Advanc. Pharmacol. 6B, 29–47 (1968).
Kopin, I.J.: Catecholamines in blood pressure regulation. In: L-Dopa and Parkinsonism, pp. 277–280, edit. A. Barbeau And F.H. Mcdowell. Philadelphia: Davis 1970.
Korduba, C.A., Veals, J., Symchowicz, S.: Effect of glucocorticoids on 14C-dopamine metabolism in rat brain. Pharmacologist 12, 287 (1970).
Kormano, M.: Distribution of injected L–3, 4-dihydroxyphenylalanine (L-dopa) in the adult rat testis and epididymis. Acta physiol. scand. 71, 125–126 (1967).
Krasner, N., Cornelius, J.M.: L-Dopa for postencephalitic Parkinsonism. Brit. med. J. 4, 496 (1970).
Krayenbühl, H., Siegfried, J.: Treatment of Parkinson’s disease: stereotaxic operation or L-DOPA. Neuro-chirugie 16, 71–76 (1970).
Kremer, M., Russell, W.R., Smyth, G. E.: A mid-brain syndrome following head injury. J. Neurol. Neurosurg. Psychiat. 10, 49–60 (1947).
Kuehl, F.A., Jr., Vandenheuvel, W.J.A., Ormond, R.E.: Urinary metabolites in Parkinson’s disease. Nature (Lond.) 217, 136–138 (1968).
Kuruma, I., Bartholini, G., Pletscher, A.: L-Dopa induced accumulation of 3-0-methyl-dopa in brain and heart. Europ. J. Pharmacol. 10, 189–192 (1970).
Laidlaw, P.P.: The action of tetrahydropapaveroline hydrochloride. J. Physiol. (Lond.) 40, 480–491 (1910).
Lammers, A. J. J.C., Van Rossum, J.M.: Bizarre social behaviour in rats induced by a combination of a peripheral decarboxylase inhibitor and DOPA. Europ. J. Pharmacol. 5, 103–106 (1968).
Lancaster, G., Larochelle, L., Bedard, P., Missala, K., Sourkes, T.L., Poirier, L.J.: Effect of brain lesions and of harmaline on the DOPA decarboxylase activity in the striatum of the cat. J. neurol. Sci. 11, 265–274 (1970).
Langemann, H.: Bestimmungen von Fermentaktivitäten in Geweben eines Falls von metastasierenden Karzinoid. Arch. exp. Pathol. Pharmakol. 228, 244–245 (1956).
Langemann, H., Ackermann, H.: Über die Aktivität der Aminosäuren-Decarboxylasen im Gehirn des Menschen. Helv. physiol. Acta 19, 399–406 (1961).
Langemann, H., Boner, A., Müller, P.B.: Aminosäurendecarboxylase in Phäochromocytom-und Karzinoidgewebe. Schweiz, med. Wschr. 92, 27–34 (1962).
Laverty, R., Sharman, D.F.: Modification by drugs of the metabolism of 3,4-dihydroxyphenylethylamine, noradrenaline and 5-hydroxytryptamine in the brain. Brit. J. Pharmacol. 24, 759–772 (1965).
Leon, A.S., Solomon, H.M., Ross, I., Golden, R.M., Abrams, W.B.: Cardiovascular activity of L-dopa. Clin. Res. 18, 340 (1970).
Levine, R.J., Sjoerdsma, A.: Monoamine oxidase activity in human tissues and intestinal biopsy specimens. Proc. Soc. exp. Biol. (N.Y.) 109, 225–227 (1962).
Lieberman, A.N., Pedersen, B.: Levodopa and adventitious movements. Lancet ii, 985 (1970).
Lloyd, K., Hornykiewicz, O.: Occurrence and distribution of L-DOPA decarboxylase in the human brain. Brain Res. 22, 426–428 (1970a).
Lloyd, K., Hornykiewicz, O.: Parkinson’s disease: activity of L-dopa decarboxylase in discrete brain regions. Science170, 1212–1213 (1970b).
Loizou, L.A.: Uptake of monoamines into central neurones and the blood-brain barrier in the infant rat. Brit. J. Pharmacol. 40, 800–813 (1970).
Lotti, V.J., Porter, C.C.: Potentiation and inhibition of some central actions of L(–)-dopa by decarboxylase inhibitors. J. Pharmacol, exp. Ther. 172, 406–415 (1970).
Lovenberg, W., Weissbach, H., Udenfriend, S.: Aromatic L-amino acid decarboxylase. J. biol. Chem. 237, 89–93 (1962).
Luse, S.A., Blank, W., Mettler, F.A.: L-DOPA and hyperkinesia. Fed. Proc. 29, 512 (1970).
Lycke, E., Roos, B.-E.: Effect on the monoamine metabolism of the mouse brain by experimental Herpes simplex injection. Experientia (Basel) 24, 687–689 (1968).
Lycke, E., Roos, B.-E.: Some virological and biochemical aspects of the pathogenesis of Parkinson’s disease.In: Third Symposium on Parkinson’s Disease, pp. 16–19, edit. F.J. Gillingham And I.M.L. Donaldson. Edinburgh: Livingstone 1969.
Lyman, F.L.: Phenylketonuria, Springfield: Thomas, 1963, pp. 1–318.MCCANN, D.S., MITCHELL, J.G., KEECH, M.K., BOYLE, A. J.: Tyrosine metabolism in connective tissue disease. J. chron. Dis. 20, 781–786 (1967).
Mcdowell, F.H.: Changes in behavior and mentation. In: L-Dopa and Parkinsonism, pp. 321–325, edit. A. Barbeau And F.H. Mcdowell. Philadelphia: Davis 1970.
Mcdowell, F.H., Lee, J.E., Swift, T., Sweet, R.D., Ogsbury, J.S., Kessler, J.T.: Treatment of Parkinson’s syndrome with L-dihydroxyphenylalanine (levodopa). Ann. intern. Med. 72, 29–35 (1970).
Mcgeer, P. L., Boulding, J. E., Gibson, W. C., Foulkes, R. G.: Drug-induced extrapyramidal reactions. J. Amer. med. Ass. 177, 665–670 (1961).
Mcgeer, P. L., Zeldowicz, L.R.: Administration of dihydroxyphenylalanine to parkinsonian patients. Canad. med. Ass. J. 90, 463–466 (1964).
Mcnay, J.L., Mcdonald, R.H., Goldberg, L.I.: Direct renal vasodilation produced by dopamine in the dog. Circulat. Res. 16, 510–517 (1965).
Maeda, T., Wegmann, R.: Infrared spectrometry of locus coeruleus and substantia nigra pigments in human brain. Brain Res. 14, 673–681 (1969).
Manger, W.M., Bessis, M.: White cell uptake of L-dihydroxyphenylalanine (L-DOPA), catecholamines (CAs) and 5-hydroxytryptamine (5-HT). Pharmacologist 11, 263 (1969).
Krayenbühl, H., Siegfried, J.: Treatment of Parkinson’s disease: stereotaxic operation or L-DOPA. Neuro-chirugie 16, 71–76 (1970).
Kremer, M., Russell, W.R., Smyth, G. E.: A mid-brain syndrome following head injury. J. Neurol. Neurosurg. Psychiat. 10, 49–60 (1947).
Kuehl, F.A., Jr., Vandenheuvel, W.J.A., Ormond, R.E.: Urinary metabolites in Parkinson’s disease. Nature (Lond.) 217, 136–138 (1968).
Kuruma, I., Bartholini, G., Pletscher, A.: L-Dopa induced accumulation of 3-0-methyldopa in brain and heart. Europ. J. Pharmacol. 10, 189–192 (1970).
Laidlaw, P.P.: The action of tetrahydropapaveroline hydrochloride. J. Physiol. (Lond.) 40, 480–491 (1910).
Lammers, A. J. J.C., Van Rossum, J.M.: Bizarre social behaviour in rats induced by a combination of a peripheral decarboxylase inhibitor and DOPA. Europ. J. Pharmacol. 5, 103–106 (1968).
Lancaster, G., Larochelle, L., Bedard, P., Missala, K., Sourkes, T.L., Poirier, L.J.: Effect of brain lesions and of harmaline on the DOPA decarboxylase activity in the striatum of the cat. J. neurol. Sci. 11, 265–274 (1970).
Langemann, H.: Bestimmungen von Fermentaktivitäten in Geweben eines Falls von metastasierenden Karzinoid. Arch. exp. Pathol. Pharmakol. 228, 244–245 (1956).
Langemann, H., Ackermann, H.: Über die Aktivität der Aminosäuren-Decarboxylasen im Gehirn des Menschen. Helv. physiol. Acta 19, 399–406 (1961).
Langemann, H., Boner, A., Müller, P.B.: Aminosäurendecarboxylase in Phäochromocytom-und Karzinoidgewebe. Schweiz, med. Wschr. 92, 27–34 (1962).
Laverty, R., Sharman, D.F.: Modification by drugs of the metabolism of 3,4-dihydroxy-phenylethylamine, noradrenaline and 5-hydroxytryptamine in the brain. Brit. J. Pharmacol. 24, 759–772 (1965).
Leon, A.S., Solomon, H.M., Ross, I., Golden, R.M., Abrams, W.B.: Cardiovascular activity of L-dopa. Clin. Res. 18, 340 (1970).
Levine, R.J., Sjoerdsma, A.: Monoamine oxidase activity in human tissues and intestinal biopsy specimens. Proc. Soc. exp. Biol. (N.Y.) 109, 225–227 (1962).
Lieberman, A.N., Pedersen, B.: Levodopa and adventitious movements. Lancet ii, 985 (1970).
Lloyd, K., Hornykiewicz, O.: Occurrence and distribution of L-DOPA decarboxylase in the human brain. Brain Res. 22, 426–428 (1970a).
Lloyd, K., Hornykiewicz, O.: Parkinson’s disease: activity of L-dopa decarboxylase in discrete brain regions. Science170, 1212–1213 (1970b).
Loizou, L.A.: Uptake of monoamines into central neurones and the blood-brain barrier in the infant rat. Brit. J. Pharmacol. 40, 800–813 (1970).
Lotti, V.J., Porter, C.C.: Potentiation and inhibition of some central actions of L(–)-dopa by decarboxylase inhibitors. J. Pharmacol, exp. Ther. 172, 406–415 (1970).
Lovenberg, W., Weissbach, H., Udenfriend, S.: Aromatic L-amino acid decarboxylase. J. biol. Chem. 237, 89–93 (1962).
Luse, S.A., Blank, W., Mettler, F.A.: L-DOPA and hyperkinesia. Fed. Proc. 29, 512 (1970).
Lycke, E., Roos, B.-E.: Effect on the monoamine metabolism of the mouse brain by experimental Herpes simplex injection. Experientia (Basel) 24, 687–689 (1968).
Lycke, E., Roos, B.-E.: Some virological and biochemical aspects of the pathogenesis of Parkinson’s disease.In: Third Symposium on Parkinson’s Disease, pp. 16–19, edit. F.J. Gillingham And I.M.L. Donaldson. Edinburgh: Livingstone 1969.
Lyman, F.L.: Phenylketonuria, Springfield: Thomas, 1963, pp. 1–318.MCCANN, D.S., MITCHELL, J.G., KEECH, M.K., BOYLE, A. J.: Tyrosine metabolism in connective tissue disease. J. chron. Dis. 20, 781–786 (1967).
Mcdowell, F.H.: Changes in behavior and mentation. In: L-Dopa and Parkinsonism, pp. 321–325, edit. A. Barbeau And F.H. Mcdowell. Philadelphia: Davis 1970.
Mcdowell, F.H., Lee, J.E., Swift, T., Sweet, R.D., Ogsbury, J.S., Kessler, J.T.: Treatment of Parkinson’s syndrome with L-dihydroxyphenylalanine (levodopa). Ann. intern. Med. 72, 29–35 (1970).
Mcgeer, P. L., Boulding, J. E., Gibson, W. C., Foulkes, R. G.: Drug-induced extrapyramidal reactions. J. Amer. med. Ass. 177, 665–670 (1961).
Mcgeer, P. L., Zeldowicz, L.R.: Administration of dihydroxyphenylalanine to parkinsonian patients. Canad. med. Ass. J. 90, 463–466 (1964).
Mcnay, J.L., Mcdonald, R.H., Goldberg, L.I.: Direct renal vasodilation produced by dopamine in the dog. Circulat. Res. 16, 510–517 (1965).
Maeda, T., Wegmann, R.: Infrared spectrometry of locus coeruleus and substantia nigra pigments in human brain. Brain Res. 14, 673–681 (1969).
Manger, W.M., Bessis, M.: White cell uptake of L-dihydroxyphenylalanine (L-DOPA), catecholamines (CAs) and 5-hydroxytryptamine (5-HT). Pharmacologist 11, 263 (1969).
Markham, C.H.: Major treatment problems in L-dopa therapy in Parkinson’s disease. In: L-Dopa and Parkinsonism, pp. 10–16, edit. A. Barbeau And F.H. Mcdowell. Philadelphia: Davis 1970.
Markham, C.H., Treciokas, L., Ansel, R.D.: Blood pressure in parkinsonian patients receiving L-dopa. In: L-Dopa and Parkinsonism, pp. 255–262, edit. A. Barbeaxj And F.H. Mcdowell. Philadelphia: Davis 1970.
Marley, E., Stephenson, J.D.: Effects of catecholamines infused into the brain of young chickens. Brit. J. Pharmacol. 40, 639–658 (1970).
Marsden, D.: Brain pigment and its relation to brain catecholamines. Lancet ii, 475–476 (1965).
Masri, M.S., Booth, A.N., Deeds, F.: 0-Methylation in vitro of dihydroxy-and trihydroxyphenolic compounds by liver slices. Biochim. biophys. Acta (Amst.) 65, 495–500 (1962).
Masri, M.S., Bobbins, D.J., Emerson, O.H., Deeds, F.: Selective para-or meia-0-methylation with catechol 0-methyl transferase from rat liver. Nature (Lond.) 202, 878–879 (1964).
Matthieu, P., Revol, L.: Les metabolites 4-0-methyles des catecholamines chez l’homme: identification chromatographique de l’acide 3-hydroxy, 4-methoxyphenylacetique (acide homo-iso-vanillique, iso-HVA). Bull. Soc. Chim. biol. (Paris) 52, 1039–1050 (1970).
Matussek, N., Benkert, O., Schneider, K., Otten, H., Pohlmeier, H.: L-Dopa plus decarboxylase inhibitor in depression. Lancet ii, 660–661 (1970).
Mawdsley, C.: Treatment of Parkinsonism with laevo-dopa. Brit. med. J. 1, 331–337 (1970).
Medes, G.: A new error of tyrosine metabolism: tyrosinosis. The intermediary metabolism of tyrosine and phenylalanine. Biochem. J. 26, 917–940 (1932).
Mena, I., Court, J., Fuenzalida, S., Papavasiliou, P.S., Cotzias, G.C.: Modification of chronic manganese poisoning: treatment with L-dopa or 5-OH tryptophane. New Engl. J. Med. 282, 5–10 (1970).
Mena, I., Marin, O., Fuenzalida, S., Cotzias, G.C.: Chronic manganese poisoning: clinical picture and manganese turnover. Neurology 17, 128–136 (1967).
Mendell, J.R., Chase, T.N., Engel, W.K.: Modification by L-dopa of a case of progressive supranuclear palsy with evidence of defective cerebral dopamine metabolism. Lancet i, 593–594 (1970).
Mendlowitz, M., Wolf, R.L., Gitlow, S.E.: Catecholamine metabolism in essential hypertension. Amer. Heart J. 79, 401–407 (1970).
Messiha, F.S., Agallianos, D., Clower, C.: Dopamine excretion in affective states and following Li2 C03 therapy. Nature (Lond.) 225, 868–869 (1970).
Metzel, E., Weinmann, D., Riechert, T.: A study of the enzymes of dopa metabolism in parkinsonism from biopsies of the basal ganglia. In: Third Symposium on Parkinson’s Disease, pp. 47–50, edit. F.J. Gillingham And I.M.L. Donaldson. Edinburgh: Living-stone 1969.
Michelakis, A.M., Robertson, D.: Plasma renin activity and levodopa in Parkinsonism. J. Amer. med. Ass. 213, 83–85 (1970).
Mitoma, C., Posner, H.S., Bogdanski, D.F., Udenfriend, S.: Biochemical and pharmacological studies on o-tyrosine and its meta-and para-analogues; a suggestion concerning phenylketonuria. J. Pharmacol, exp. Ther. 120, 188–194 (1957).
Mjones, H.: Paralysis agitans. A clinical and genetic study. Acta psychiat. neurol. scand. Suppl. 54, pp. 1–195 (1949).
Moir, A.T.B., Ashcroft, G.W., Crawford, T.B.B., Eccleston, D., Guldberg, H.C.: Cerebral metabolites in cerebrospinal fluid as a biochemical approach to the brain. Brain 93, 357–368 (1970).
Molinoff, P.B.: Personal communication (1970).
Molinoff, P., Axelrod, J.: Octopamine: normal occurrence in sympathetic nerves of rats. Science 164, 428–429 (1969).
Mones, R.J., Elizan, T.S., Siegel, G.J.: Evaluation of L-dopa therapy in Parkinson’s disease. N.Y. St. J. Med. 70, 2309–2318 (1970).
Montplaisir, J., Barbeau, A.: Serum tyrosine in Parkinson’s disease. In: Progress in Neurogenetics, pp. 331–335, edit. A. Barbeau And J.R. Brunette, International Congress Series No. 175. Amsterdam: Excerpta Medica Foundation 1969.
Morgan, C.D., Ruthven, C.R.J., Sandler, M.: The quantitative assessment of isoprenaline metabolism in man. Clin. chim. Acta 26, 381–386 (1969).
Morgan, J. P., Preziosi, T.J., Bianchine, J.R.: Ineffectiveness of L-dopa as supplement to penicillamine in a case of Wilson’s disease. Lancet ii, 659 (1970a).
Morgan, J. P., Spiegel, H.E., Hersey, R.M., Calimlim, L.R., Bianchine, J.R.: Metabolism of oral L-dopa in parkinsonian patients. Clin. Res. 18, 342 (1970b).
Müller-Calgan, H., Sommer, S.: Das Reserpin-Parkinsonoid beim Schimpansen und seine Behandlung mit Fencamfamin. Arch. Pharmakol. exp. Path. 260, 177 (1968).
Murphy, G.F., Robinson, D., Sharman, D.F.: The effect of tropolone on the formation of 3,4-dihydroxyphenylacetic acid and 4-hydroxy–3-methoxyphenylacetic acid in the brain of the mouse. Brit. J. Pharmacol. 36, 107–115 (1969).
Nagatsu, T., Levitt, M., Udenfriend, S.: Tyrosine hydroxylase. The initial step in nor-epinephrine biosynthesis. J. biol. Chem. 239, 2910–2917 (1964).
Neff, N.H., Barrett, R.E., Costa, E.: Selective depletion of caudate nucleus dopamine and serotonin during chronic manganese dioxide administration to squirrel monkeys. Experien-tia (Basel) 25, 1140–1141 (1969).
Ng, K.Y., Chase, T.N., Colburn, R.W., Kopin, I.J.: L-Dopa-induced release of cerebral monoamines. Science 170, 76–77 (1970).
O’Gorman, L.P., Borud, O., Khan, I.A., Gjessing, L.R.: The metabolism of L–3,4-di-hydroxyphenylalanine in man. Clin. chim. Acta 29, 111–119 (1970).
O’Keefe, R., Sharman, D.F., Vogt, M.: Effects of drugs used in psychoses on cerebral dopamine metabolism. Brit. J. Pharmacol. 38, 287–304 (1970).
Olsson, R., Roos, B.-E.: Concentrations of 5-hydroxyindoleacetic acid and homovanillic acid in the cerebrospinal fluid after treatment with probenecid in patients with Parkinson’s disease. Nature (Lond.) 219, 502–503 (1968).
Pakkenberg, H., Brody, H.: The number of nerve cells in the substantia nigra in paralysis agitans. Acta neuropath. (Berl.) 5, 320–324 (1965).
Palm, D.: Über die Hemmung der Dopa-Decarboxylase durch Isonicotinsäurehydrazid. Arch. exp. Pathol. Pharmakol. 234, 206–209 (1958).
Papeschi, R., Molina-Negro, P., Sourkes, T.L., Hardy, J., Bertrand, C.: Concentration of homovanillic acid in the ventricular fluid of patients with Parkinson’s disease and other dyskinesias. Neurology 20, 991–995 (1970).
Pare, C.M.B., Sandler, M.: A clinical and biochemical study of a trial of iproniazid in the treatment of depression. J. Neurol. Neurosurg. Psychiat. 22, 247–251 (1959).
Pare, C.M.B., Stacey, R. S.: 5-Hydroxytryptamine deficiency in phenylketonuria. Lancet i, 551–553(1957).
Pare, C.M.B., Stacey, R. S.: Decreased 5-hydroxytryptophan decarboxylase activity in phenylketonuria.Lancet ii, 1099–1101 (1958).
Pare, C.M.B., Stacey, R. S.: The relationship between increased 5-hydroxyindole metabolism and mental defectin phenylketonuria. Arch. Dis. Childh. 34, 422–423 (1959).
Pare, C.M.B., Yeung, D.P.H., Price, K., Stacey, R.S.: 5-Hydroxytryptamine, noradrenaline and dopamine in brainstem, hypothalamus, and caudate nucleus of controls and of patients committing suicide by coal-gas poisoning. Lancet ii, 133–135 (1969).
Parkes, J.D., Sharpstone, P., Williams, R.: Levodopa in hepatic coma. Lancet ii, 1341–1343 (1970a).
Parkes, J.D., Zilkha, K.J., Calver, D.M., Knill-Jones, R.P.: Controlled trial of amantadine hydrochloride in Parkinson’s disease. Lancet i, 259–262 (1970b).
Parkinson, J.: An essay on the shaking palsy, pp. 1–66. London: Sherwood, Neely and Jones 1817.PEASTON, M.J.T., BIANCHINE, J.R.: Metabolic studies and clinical observations during L-dopa treatment of Parkinson’s disease. Brit. med. J. 1, 400–403 (1970).
Penttilä, O., Vartiainen, A.: Acetylcholine, histamine, 5-hydroxytryptamine and catecholamine contents of mammalian penile and urethral tissue. Acta pharmacol. (Kbh.) 21, 145–151 (1964).
Pepeu, G., Giarman, N.J.: Serotonin in the developing mammal. J. gen. Physiol. 45, 575–583 (1962).
Perry, T.L., Hestrin, M., Macdougall, L., Hansen, S.: Urinary amines of intestinal bacterial origin. Clin. chim. Acta 14, 116–123 (1966).
Peters, D.A.V., Mcgeer, P.L., Mcgeer, E.G.: The distribution of tryptophan hydroxylase in cat brain. J. Neurochem. 15, 1431–1435 (1968).
Pinder, R.M.: Possible dopamine derivatives capable of crossing the blood-brain barrier in relation to parkinsonism. Nature (Lond.) 228–229 (1970).
Pletscher, A., Bartholini, G., Tissot, R.: Metabolic fate of L-(14C) dopa in cerebrospinal fluid and blood plasma of humans. Brain Res. 4, 106–109 (1967).
Pogrund, R.S., Drell, W., Clark, W.G.: Metabolism of 3-hydroxy-and 3,4-dihydroxy-phenylpyruvic acids in vivo. J. Pharmacol, exp. Ther. 131, 294–307 (1961).
Poirier, L. J.: Experimental and histological study of midbrain dyskinesias. J. Neurophysiol. 23, 534–551 (1960).
Poirier, L. J., Singh, P., Boucher, R.: Opposite effect of harmaline on serotonin and on dopamine and its metabolites, homovanillic acid and norepinephrine, in the brain of the cat. Canad. J. Physiol. Pharmacol. 46, 585–589 (1968).
Poirier, L.J., Singh, P., Sourkes, T.L., Boucher, R.: Effect of amine precursors on the concentration of striatal dopamine and serotonin in cats with and without unilateral brain stem lesions. Brain Res. 6, 654–666 (1967).
Poirier, L.J., Sourkes, T.L.: Influence of the substantia nigra on the catecholamine content of the striatum. Brain 88, 181–192 (1965).
Porter, C.C., Watson, L.S., Titus, D.C., Totaro, J.A., Byer, S.S.: Inhibition of dopa decarboxylase by the hydrazino analog of α-methyldopa. Biochem. Pharmacol. 11, 1067–1077 (1962).
Pullar, I.A., Weddell, J.M., Hanieh, A., Ahmed, R., Gillingham, F. J.: Changes in acid metabolites of dopamine and 5-hydroxytryptamine in lumbar CSF of patients treated with L-DOPA. Proc. 2nd int. Meeting int. Soc. Neurochem., Milan, pp. 328–329 (1969).
Pushpathadam, J.J., Barbeau, A.: The ‘pink spot’ and Parkinson’s disease. In: Progress in Neurogenetics, pp. 413–417, edit. A. Barbeau And J.R. Brunette, International Congress Series No. 175. Amsterdam: Excerpta Medica Foundation 1969.
Rao, N.S.: Effects of withdrawing dopa in Parkinson’s disease. Lancet ii, 470–471 (1970).
Rennick, B.R.: Dopamine: renal tubular transport in the dog and plasma building studies. Amer. J. Physiol. 215, 532–534 (1968).
Renson, J., Weissbach, H., Udenfriend, S.: Studies on the biological activities of the aldehydes derived from norepinephrine, serotonin, tryptamine and histamine. J. Pharmacol. exp. Ther. 143, 326–331 (1964).
Resnick, R.H., Gray, S.J., Koch, J. P., Timberlake, W.H.: Serotonin metabolism in paralysis agitans. Proc. Soc. exp. Biol. (N.Y.) 110, 77–79 (1962).
Rinne, U.K., Sonninen, V.: Homovanillic acid of the cerebrospinal fluid in Parkinson’s disease. Scand. J. clin. Lab. Invest. Suppl. 101, p. 22 (1968a).
Rinne, U.K., Sonninen, V.: A double blind study of 1-dopa treatment in Parkinson’s disease. Europ. Neurol. 1, 180–191 (1968b).
Rinne, U.K., Sonninen, V.: Catecholamines in Parkinson’s disease. Acta neurol. scand. 46, Suppl. 43, 217 (1970).
Rivera-Calimlim, L., Dujovne, C.A., Morgan, J.P., Lasagna, L., Bianchine, J.R.: L-Dopa absorption and metabolism by the human stomach. Pharmacologist 12, 269 (1970a).
Rivera-Calimlim, L., Dujovne, C.A., Morgan, J.P., Lasagna, L., Bianchine, J.R.: L-Dopa treatment failure: explanation and correction. Brit. med. J. 4, 93–94 (1970b).
Rivera-Calimlim, L., Morgan, J.P., Dujovne, C.A., Bianchine, J.R., Lasagna, L.: L-Dopa metabolism by rat gut in vitro. Clin. Res. 18, 343 (1970c).
Robins, E., Robins, J.M., Croninger, A.B., Moses, S.G., Spencer, S.J., Hudgens, R.W.: The low level of 5-hydroxytryptophan decarboxylase in human brain. Biochem. Med. 1, 240 (1967).
Roos, B.-E.: Decrease in homovanillic acid as evidence for dopamine receptor stimulation by apomorphine in the neostriatum of the rat. J. Pharm. Pharmacol. 21, 263–264 (1969).
Roos, B.-E., Sjöström, R.: 5-Hydroxyindoleacetic acid (and homovanillic acid) levels in the cerebrospinal fluid after probenecid application in patients with manic depressive psychosis. Pharmacol. Clin. 1, 153–155 (1969).
Rose, C.M., Chou, C., Wurtman, R.J.: The metabolism of 14C-dopa in the whole mouse. Fed. Proc. 29, 511 (1970).
Rosell, S., Sedvall, G., Ullberg, S.: Distribution and fate of dihydroxyphenylalanine–2–14C (DOPA) in mice. Biochem. Pharmacol. 12, 265–269 (1963).
Rosen, J.A.: The effect of a monoamine oxidase inhibitor on the bradykinesia of human parkinsonism. In: Progress in Neuro-genetics, 1, pp. 346–351, edit. A. Barbeau And J.R. Brunette, Int. Congr. Series No. 175. Amsterdam: Excerpta Medica Foundation 1969.
Rosenmund, K.W., Dornsaft, H.: Über Oxy-und Dioxyphenylserin und die Muttersubstanz des Adrenalins. Ber. dtsch. ehem. Ges. 52, 1734–1749 (1919).
Roy, S., Wolman, L.: Ultrastructural observations in parkinsonism. J. Path. 99, 39–44 (1969).
Ruthven, C.R. J., Karoum, F., Anah, C.O., Chapman, J., Sandler, M.: The study of catecholamine secreting tumours by gas-liquid chromatography. Enzym, biol. clin. 10, 456 (1969).
Sabuncu, N.: Quantitative Untersuchungen am Pallidum beim Parkinson-Syndrom. Dtsch. Z. Nervenheilk. 196, 40–48 (1969).
Sacks, O.W., Kohl, M.: Incontinent nostalgia induced by L-dopa. Lancet i, 1394 (1970a).
Sacks, O.W., Kohl, M.: L-Dopa and oculogyric crises. Lancet ii, 215–216 (1970b).
Sacks, O.W., Schwartz, W.F., Messeloff, C.R.: Side-effects of L-dopa in postencephalitic parkinsonism. Lancet i, 1006 (1970a).
Sacks, O.W., Messeloff, C.R., Schwartz, W.F.: Long-term levodopa in the severely disabled. J. Amer. med. Ass. 213, 2270 (1970b).
Sacks, O.W., Messeloff, C.R., Schwartz, W.F., Goldfarb, A., Kohl, M.: Effects of L-dopa in patients with dementia. Lancet i, 1231 (1970c).
Sandler, M.: The role of 5-hydroxyindoles in the carcinoid syndrome. Advanc. Pharmacol. 6B, 127–142 (1968).
Sandler, M.: Biosynthesis and metabolism of the catecholamines. Schweiz, med. Wschr. 100, 526–531 (1970a).
Sandler, M.: The role of minor pathways of dopa metabolism. In: L-Dopa and Parkinsonism, pp. 72–75, edit. A. Barbeau And F.H. Mcdowell. Philadelphia: Davis 1970b.
Sandler, M.: Discussion remark. In: L-Dopa and Parkinsonism, p. 251, edit. A. Barbeau And F.H. Mcdowell, Philadelphia: Davis 1970c.
Sandler, M.: In preparation (1971).
Sandler, M., Collins, G.G.S., Youdim, M.B.H.: Inhibition patterns of monoamine oxidase isoenzy-mes: clinical implications. In: Mechanisms of Toxicity, pp. 3–11, edit. W.N. Aldridge. London: Macmillan 1971a.
Sandler, M., Goodwin, B.L., Ruthven, C.R.J., Calne, D.B.: m-Tyramine formation from L-dopa in man: therapeutic implications in Parkinsonism. Nature (Lond.) 229, 414–415 (1971b).
Sandler, M., Karoum, F., Ruthven, C.R.J.: Parkinsonism with alkaptonuria: a new syndrome ? Lancet ii, 770 (1970a).
Sandler, M., Calne, D.B.: M-Hydroxyphenylacetic acid formation from L-dopa in man:suppression by neomycin. Science 166, 1417–1418 (1969a).
Southgate, J., Calne, D.B.: Metabolism of L-DOPA in Parkinsonism. Abstr.4th int. Congr. Pharmacol., Basel, p. 81 (1969b).
Southgate, J., Calne, D.B., Ruthven, C.R.J.: 4-Hydroxy–3-methoxyphenylglycol and other compounds in neuroblastoma. In: Recent Results in Cancer Research. II. Neuroblastomas. Biochemical Studies, pp. 55–59, edit. C. Bohuon. Berlin: Springer 1966.
Southgate, J., Calne, D.B., Ruthven, C.R.J.: The biosynthesis and metabolism of the catecholamines. In: Progress in MedicinalChemistry, edit. G.P. Ellis and G.B. West, Vol. 6, pp. 200–265. London: Butterworth 1969.
Southgate, J., Calne, D.B., Ruthven, C.R.J.: Monoamine-secreting tumours. In: Tumours in Children, edit. A.E. Claireaux.Springfield: Thomas 1972, in the press.
Southgate, J., Caesar, P.M.: Urinary pH and the excretion of biologically active amines and theiracidic metabolites. Proc. 7th int. Congr. Biochem. Tokyo, 1967, p. 971.
Southgate, J., Youdim, M.B.H., Southgate, J., Hanington, E.: The role of tyramine in migraine: some possible biochemical mechanisms. In: Background to Migraine. 3rd Migraine Symposium, pp. 104–115, edit. A.L. Cochrane. London: Heinemann 1970b.
Scheckel, C.L., Boff, E., Pazery, L.M.: Behavioral and biochemical effects of interacting 3,4-dihydroxyphenylalanine (DOPA) and an inhibitor of aromatic acid decarboxylase (Ro4–4602). Fed. Proc. 24, 195 (1965).
Scheckel, C.L., Boff, E., Pazery, L.M.: Hyperactive states related to the metabolism of norepinephrine and similar biochemicals. Ann. N.Y. Acad. Sci. 159, 939–958 (1969).
Scheline, R. R.: Drug metabolism by intestinal microorganisms. J. pharm. Sci. 57, 2021–2037 (1968a).
Scheline, R. R., Midtvedt, T.: Absence of dehydroxylation of caffeic acid in germfree rats. Experientia (Basel) 26, 1068–1069 (1970).
Schmiterlöw, C.G.: Formation in vivo of noradrenaline from 3,4-dihydroxyphenylserine (noradrenaline carboxylic acid). Brit. J. Pharmacol. 6, 127–134 (1951).
Schnieden, H., Williams, T.: Effect of thalamotomy on urinary dopamine levels in patients with parkinsonism. Europ. Neurol. 3, 290–292 (1970).
Schott, H.F., Clark, W.G.: DOPA decarboxylase inhibition through the interaction of coenzyme and substrate. J. biol. Chem. 196, 449–462 (1952).
Schwab, R.S.: Combining L-dopa and amantadine hydrochloride (Symmetrel). In: L-Dopa and Parkinsonism, p. 58, edit. A. Barbeau And F.H. Mcdowell. Philadelphia: Davis 1970.
Schwab, R.S., Amador, L.V., Lettvin, J.Y.: Apomorphine in Parkinson’s disease. Trans. Amer. neurol. Ass. 76, 251–253 (1951).
Schwab, R.S., England, A.C., Jr., Poskanzer, D.C., Young, R.R.: Amantadine in Parkinson’s disease. J. Amer. med. Ass. 208, 1168–1170 (1969).
Schwarz, G.A., Fahn, S.: Newer medical treatments in parkinsonism. Med. Clin. N. Amer. 54, 773–785 (1970).
Scott, J.A.: 3,4-Dihydroxyphenylalanine (dopa) excretion in patients with malignant melanoma. Lancet ii, 861–862 (1962).
Sealock, R.R.: β-3,4-Dihydroxyphenyl-L-alanine. Biochem. Prep. 1, 25–33 (1949).
Segal, D.S., Whalen, R.E.: Effect of chronic administration of p-chlorophenylalanine on sexual receptivity of the female rat. Psychopharmacologia (Berl.) 16, 434–438 (1970).
Sekeris, C.E., Herrlich, P.: Nachweis von N-Acetyl-dopamin bei einem Fall von Phaochromocytom. Z. physiol. Chem. 331, 289–291 (1963).
Sekeris, C.E., Karlson, P.: Biosynthesis of catecholamines in insects. Pharmacol. Rev. 18, 89–94 (1966).
Semba, T., Civen, M.: Subcellular distribution of aromatic amino acid transaminases in rat brain. J. Neurochem. 17, 795–800 (1970).
Senoh, S., Daly, J., Axelrod, J., Witkop, B.: Enzymatic p-0-methylation by catechol-0-methyl transferase. J. Amer. ehem. Soc. 81, 6240–6245 (1959a).
Senoh, S., Witkop, B., Crevelixg, C.R., Udenfriend, S.: 2,4,5-Trihydroxyphenylethylamine, a new metabolite of 3,4-dihydroxyphenylethylamine. J. Amer. ehem. Soc. 81, 1768–1769 (1959b).
Serrano, P.: Personal communication to SOURKES, T.L.: On the mode of action of L-dopa in Parkinson’s disease. Biochem. Med. 3, 321–325 (1970).
Shah, N.S., Kamano, A., Glisson, S., Callison, D.: Studies on the uptake of radiolabeled DOPA, 5-HTP and tryptophan in rat tissues in vivo: effect of methionine, tryptophan and some keto acids. Int. J. Neuropharmacol. 7, 75–86 (1968).
Sharman, D.P.: The effect of drugs on the metabolism of dopamine in the striatum. In: Third Symposium on Parkinson’s Disease, pp. 24–26, edit. F.J. Gillingham And I.M.L. Donaldson. Edinburgh: Livingstone 1969.
Sharman, D.P., Poirier, L.J., Murphy, G.F., Sourkes, T.L.: Homovanillic acid and dihydroxyphenylacetic acid in the striatum of monkeys with brain lesions. Canad. J. Physiol. 45, 57–62 (1967).
Shaw, K.N.F., Gutenstein, M., Jepson, J.B.: Intestinal flora and diet in relation to m-hydroxyphenyl acids of human urine. Proc. 5th int. Cong. Biochem. Moscow, Vol. 9, p. 427. Oxford: Pergamon 1961.
Shaw, K.N.F., Mcmillan, A., Armstrong, M.D.: The metabolism of 3,4-dihydroxyphenylalanine. J. biol. Chem. 226, 255–266 (1957).
Shealy, C.N., Weeth, J.B., Mercier, D.: Livedo reticularis, parkinsonism and amantadine. J. Amer. med. Ass. 212, 1522–1523 (1970).
Shulgin, A.T., Sargent, T., Naranjo, C.: Structure-activity relationships of onering psychotomimetics. Nature (Lond.) 221, 537–541 (1969).
Shy, M., Drager, G.: A neurological syndrome associated with orthostatic hypotension. Arch. Neurol. 2, 41–57 (1960).
Siegfried, J.: Deux ans d’expérience avec la L-DOPA associée à un inhibiteur de la décar-boxylase. Rev. Neurol. 122, 243–248 (1970).
Sigwald, J., Raymondeaud, C.: Les movements abnormaux observés au cours du traitement de la maladie de Parkinson par la L-dopa. Rev. Neurol, 122, 103–112 (1970).
Sih, C.J., Foss, P., Rosazza, J., Lemberger, M.: Microbiological synthesis of L–3,4-dihy-droxyphenylalanine. J. Amer. chem. Soc. 91, 6204 (1969).
Simek, J.: Vylucovani kyseliny 3-metoxy 4-hydroxyfenyloctové (homovanilové) u parkinsonikû. Cas. Lék. ëesk. 107, 544–546 (1968).
Sjoerdsma, A.: Techniques for measuring monoamine oxidase inhibiting activity in man. J. Neuropsychiat. 2, S159–S162 (1961).
Sjoerdsma, A., Engelman, K., Spector, S., Udenfriend, S.: Inhibition of catecholamine synthesis in man with alpha-methyl-tyrosine, an inhibitor of tyrosine hydroxylase. Lancet ii, 1092–1094 (1965).
Sjoerdsma, A., Lovenberg, W., Engelman, K., Carpenter, W.T., Jr., Wyatt, R.J., Gessa, G.L.: Serotonin now: clinical implications of inhibiting its synthesis with para-chlorophenyl-alanine. Ann. intern. Med. 73, 607–629 (1970).
Smellie, J.M., Sandler, M.: Secreting intrathoracic ganglioneuroma. Proc. roy. Soc. Med. 54, 327–329 (1961).
Smith, A.A., Fabrykant, M., Kaplan, M.,Gavitt, J.: Dehydroxylation of some catecholamines and their products. Biochim. biophys. Acta (Amst.) 86, 429–437 (1964).
Smith, I., Kellow, A.H.: Aromatic amines and Parkinson’s disease. Nature (Lond.) 221, 1261 (1969).
Smith, I., Hanington, E.: Tyramine metabolism in dietary migraine. In: Background to Migraine. Third Migraine Symposium, p. 120–124, edit. A.L. Cochrane. London: Heinemann 1970a.
Smith, I., Mullen, P.E., Hanington, E.: Dietary migraine and tyramine metabolism. A possibleinborn error of conjugation. Nature (Lond.) 230, 246–248 (1971).
Smith, J.S., Brandon, S.: Acute carbon monoxide poisoning–3 years’ experience in a defined population. Postgrad, med. J. 46, 65–70 (1970).
Smith, P.: Metabolism of dihydroxyphenylalanine in human subjects. Nature (Lond.) 213, 802–803 (1967).
Smith, R.L.: The role of the gut flora in the conversion of inactive compounds to active metabolites. In: Mechanisms of Toxicity, edit. W.N. Aldridge. London: Maemillan 1971, pp. 229–241.
Smythies, J.R.: Schizophrenia: chemistry, metabolism and treatment, pp. 1–86. Springfield: Thomas 1963.
Smythies, J.R., Johnston, V.S., Bradley, R.J., Benington, F., Morin, R.D., Clark, L.C., Jr.: Some new behaviour-disrupting amphetamines and their significance. Nature (Lond.) 216, 128–129 (1967).
Snyder, S.H., Coyle, J.T.: Regional differences in H3-norepinephrine and H3-dopamine uptake into rat brain homogenates. J. Pharmacol, exp. Ther. 165, 78–86 (1969).
Snyder, S.H., Taylor, K.M., Coyle, J.T., Meyerhoff, J.L.: The role of brain dopamine in behavioral regulation and the actions of psychotropic drugs. Amer. J. Psychiat. 127, 199–207 (1970).
Solomon, H.M., Spirt, N.M., Abrams, W.B.: The accumulation and metabolism of dopamine by the human platelet. Clin. Pharmacol. Ther. 11, 838–845 (1970).
Sonneville, P.F.: An indirect action of dopamine on the rat fundus strip mediated by 5-hydroxytryptamine. Europ. J. Pharmacol. 2, 367–370 (1968).
Sourkes, T.L.: On the mode of action of L-dopa in Parkinson’s disease. Biochem. Med. 3, 321–325 (1970).
Sourkes, T.L., Denton, R.L., Murphy, G.F., Chavez, B., Saint Cyr, S.: The excretion of dihydroxyphenylalanine, dopamine, and dihydroxyphenylacetic acid in neuroblastoma. Pediatrics 31, 660–668 (1963).
Sourkes, T.L., Missala, K.: Metabolism of dihydroxyphenylalanine and tryptophan in pyridoxinedeficient rats. Ann. N.Y. Acad. Sci. 159, 235–245 (1969).
Sourkes, T.L., Murphy, G.F., Rabinovitch, A.: Conversion of DL-m-tyrosine to dopamine in the rat. Nature (Lond.) 189, 577–578 (1961).
Sourkes, T.L., Pivnicki, D., Brown, W.T., Wiseman-Distler, M.H., Murphy, G.F., Sankoff, I., Saint Cyr, S.: A clinical and metabolic study of dopa (3,4-dihydroxyphenylalanine) and methyldopa in Huntington’s chorea. Psychiat. et Neurol. (Basel) 149, 7–27 (1965).
Sourkes, T.L., Poirier, L. J.: Amines of the striatum: relation to experimental tremor in the monkey. In: Biochemistry and Pharmacology of the Basal Ganglia, pp. 187–190, edit. E. Costa, L.H. Coté And M.D. Yahr. Hewlett, N.Y.: Raven Press 1966.
Singh, P.: Biochemical-histological-neurological models of Parkinson’s disease. In:Third Symposium on Parkinson’s Disease, pp. 54–60, edit. F.J. Gillingham And I.M.L. Donaldson. Edinburgh: Livingstone 1969.
Spector, S., Sjoerdsma, A., Udenfriend, S.: Blockade of endogenous norepinephrine synthesis by α-methyl-tyrosine, an inhibitor of tyrosine hydroxylase. J. Pharmacol, exp. Ther. 147, 86–95 (1965).
Stacey, R.S.: Clinical aspects of cerebral and extracerebral 5-hydroxytryptamine. In: Handbuch der experimentellen Pharmakologie, Vol. XIX, 5-Hydroxytryptamine and Related Indolealkylamines, pp. 744–786, edit. V. Erspamer. Berlin: Springer 1966.
Steg, G.: Side-effects during treatment with L-DOPA in Parkinsonism. Proc. 9th int. Congr. Neurol., N.Y., pp. 171–172 (1969).
Stellar, S., Mandell, S., Waltz, J.M., Cooper, I.S.: L-Dopa in the treatment of Parkinsonism. A preliminary appraisal. J. Neurosurg. 32, 275–280 (1970).
Stern, G.: The effect of lesions in the substantia nigra. Brain 89, 449–478 (1966).
Stock, R.: 2-Amino–4-hydroxy–6–7-dimethyl-tetrahydropteridine in Parkinson’s disease. J. Amer. med. Ass. 210, 1594 (1969).
Tagliamonte, A., Tagliamonte, P., Gessa, G.L., Brodie, B.B.: Compulsive sexual activity induced by p-chlorophenylalanine in normal and pinealectomized male rats. Science 166, 1433–1435 (1969).
Tamarkin, N.R., Goodwin, F.K., Axelrod, J.: Rapid elevation of biogenic amine metabolites in human CSF following probenecid. Life Sci. Pt. I. 9, 1397–1408 (1970).
Tamer, A., Mckey, R., Arias, D., Worley, L., Fogel, B.J.: Phenothiazine Hinduced extrapyramidal dysfunction in the neonate. J. Pediat. 75, 479–480 (1969).
Taylor, K.M., Laverty, R.: The metabolism of tritiated dopamine in regions of the rat brain in vivo.–II. The significance of the neutral metabolites of catecholamines. J. Neurochem. 16, 1367–1376 (1969).
Taylor, K.M., Snyder, S.H.: Amphetamine: differentiation by d and I isomers of behavior involving brain norepinephrine or dopamine. Science 168, 1487–1489 (1970).
Theiss, E., Scharer, K.: Toxicity of L-dopa and a decarboxylase inhibitor in animal experiments. Proc. 4th Bel-Air Symposium, Geneva, 1970, in the press.
Thoenen, H., Haefely, W., Gey, K.F., Huerlimann, A.: Quantitative aspects of the repla-cement of norepinephrine by dopamine as sympathetic transmitter after inhibition of dopamines-hydroxylase by disulfiram. J. Pharmacol, exp. Ther. 156, 246–251 (1967).
Tissot, R.: Communication to 4th Bel-Air Symposium, Geneva (1970).
Tissot, R., Pletscher, A., Bartholini, G., Constantinidis, J.: La barrière enzymatique pour la L-dopa au des capillaires du cerveau et son abolition. Proc. 2nd int. Meeting int. Soc. Neurochem. Milan, pp. 394–396 (1969c).
Tobias, J.A.Y.: Levodopa and schizophrenia. J. Amer. med. Ass. 211, 1857 (1970).
Torquati, T.: Sulla presenza di una sostanza azotata nei germogli dei semi di “Vicia faba”. Arch. Farmacol. sper. 15, 213–223 (1913).
Tseng, L.F., Walaszek, E. J.: Influence of alteration of catecholamine and serotonin levels on bulbocapnine-induced catatonia. Pharmacologist 12, 198 (1970).
Tyce, G.M.: The metabolism of L-dihydroxyphenylalanine–14C by isolated perfused rat liver. In: L-Dopa and Parkinsonism, pp. 86–88, edit. A. Barbeau And F.H. Mcdowell. Philadelphia: Davis 1970.
Tyce, G.M., Muenter, M.D., Owen, C.A., Jr.: Dihydroxyphenylalanine (dopa) in plasma during dopa treatment of patients with Parkinson’s disease. Mayo Clin. Proc. 45, 438–443 (1970a).
Tyce, G.M., Muenter, M.D., Owen, C.A., Jr.: Metabolism of L-dihydroxyphenylalanine by patients with Parkinson’s disease.Mayo Clin. Proc. 45, 645–656 (1970b).
Udenfriend, S.: Tyrosine hydroxylase. Pharmacol. Rev. 18, 43–51 (1966).
Udenfriend, S.: Biochemical investment, clinical dividend. Hosp. Pract. 4, 33–34 (1969).
Udenfriend, S., Zaltzman-Nirenberg, P., Nagatsu, T.: Inhibitors of purified beef adrenal tyrosine hydroxylase. Biochem. Pharmacol. 14, 837–845 (1965).
Ungerstedt, U., Butcher, L.L., Butcher, S.G., Anden, N.-E., Fuxe, K.: Direct chemical stimulation of dopaminergic mechanisms in the neostriatum of the rat. Brain Res. 14, 461–471 (1969).
Vander Wende, C., Johnson, J.C.: Interaction of serotonin with the catecholamines. –1. Inhibition of dopamine and norepinephrine oxidation. Biochem. Pharmacol. 19, 1991– 2000 (1970).
Vander Wende, C., Spoerlein, M.T.: Oxidation of dopamine to melanin by an enzyme of rat brain. Life Sci. 2, 386–392 (1963).
Van Rossum, J. M.: The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. Arch. int. Pharmocodyn. 160, 492–494 (1966).
Van Rossum, J. M.: The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. Arch. int. Pharmocodyn. 160, WIJFFELS, C.C.B., RIJNUES, N. V.M.: Autoradiography of 14C-DOPA in gerbils. Europ. J. Pharmacol. 7, 337–341 (1969).
Van Woert, M.H., Bowers, M.B., Jr.: The effect of L-dopa on monoamine metabolites in Parkinson’s disease. Experientia (Basel) 26, 161–163 (1970).
Van Woert, M.H., Heninger, G., Rathey, V., Bowers, M.B., Jr.: L-Dopa in senile dementia. Lancet i, 573–574 (1970).
Van Woert, M.H., Prasad, K.N., Borg, D.C.: Spectroscopic studies of substantia nigra pigment in human subjects. J. Neurochem. 14, 707–716 (1967).
Vogel, W.H.: Non-enzymatic decarboxylation of dihydroxyphenylalanine. Naturwissen-schaften 56, 462 (1969).
Vogel, W.H., Mcfarland, H., Prince, L.N.: Decarboxylation of 3,4-dihydroxyphenylalanine in various human adult and fetal tissues. Biochem. Pharmacol. 19, 618–620 (1970a).
Vogel, W.H., Orfei, V., Century, B.: Activities of enzymes involved in the formation and destruction of biogenic amines in various areas of human brain. J. Pharmacol, exp. Ther. 165, 196–203 (1969).
Vogel, W.H., Snyder, R., Hare, T.A.: The enzymatic decarboxylation of DOPA in human liver homogenates. Proc. Soc. exp. Biol. (N. Y.) 134, 477–481 (1970b).
Vogt, M.: Drug-induced changes in brain dopamine and their relation to Parkinsonism. Sci. Basis Med. pp. 276–291 (1970).
Von Studnitz, W.: Methodische und klinische Untersuchungen über die Ausscheidung der 3-Methoxy–4-Hydroxymandelsäure im Urin. Scand. J. clin. Lab. Invest. 12, Suppl. 48, 1–58 (1960).
Von Studnitz, W.: Occurrence, isolation and identification of 3-methoxy–4-hydroxyphenylalanine. Clin. chim. Acta 6, 526–530 (1961).
Von Studnitz, W.: Zur Frage des Vorkommens von 3-Hydroxy–4-methoxymandelsäure beim normalen und gesteigerten Katecholaminstoffwechsel. Klin. Wschr. 45, 307–308 (1967).
Walsh, M.J., Davis, V.E., Yamanaka, Y.: Tetrahydropapaveroline: an alkaloid metabolite of dopamine in vitro. J. Pharmacol, exp. Ther. 174, 388–400 (1970).
Ward, A.A., Jr., Mccullough, W.S., Magoun, H.W.: Production of an alternating tremor at rest in monkeys. J. Neurophysiol. 11, 317–330 (1948).
Watanabe, A.M., Chase, T.N., Cardon, P.V.: Effect of L-dopa alone and in combination with an extracerebral decarboxylase inhibitor on blood pressure and some cardiovascular reflexes. Clin. Pharmacol. Ther. 11, 740–746 (1970).
Watt, J.: Dopa and Parkinsonism. Brit. med. J. 3, 437 (1967).
Weber, W.W., Zannoni, V.G.: Reduction of phenylpyruvic acids to phenyllactic acids in mammalian tissues. J. biol. Chem. 241, 1345–1349 (1966).
Weil-Malherbe, H.: The concentration of adrenaline in human plasma and its relation to mental activity. J. ment. Sci. 101, 733–755 (1955).
Weil-Malherbe, H., Axelrod, J., Tomchick, R.: Blood-brain barrier for adrenaline. Science 129, 1226–1227 (1959).
Weil-Malherbe, H., Van Bijren, J. M.: The excretion of dopamine and dopamine metabolites in Parkinson’s disease and the effect of diet thereon. J. Lab. clin. Med. 74, 305–318 (1969).
Weiner, N.: Substrate specificity of brain amine oxidase of several mammals. Arch. Biochem. Biophys. 91, 182–188 (1960).
Weinshilboum, R., Axelrod, J.: Dopamine-β-hydroxylase activity in human blood. Phar-macologist 12, 214 (1970).
Werdinius, B.: Effect of probenecid on the levels of monoamine metabolites in the rat brain. Acta pharmacol. (Kbh.) 25, 18–23 (1967).
Werle, E., Sell, J.: Uber die fermentative Decarboxylierung von Mono-und Dioxyphenylserin. Biochem. Z. 326, 110–122 (1955).
Westlake, R.J., Tew, J.M.: Urinary amines in patient undergoing thalamotomy for Parkinson’s disease. Neurology 16, 619–620 (1966).
Wiseman-Distler, M.H., Sourkes, T.L., Carabin, S.: Precursors of 3,4-dihydroxyphenylacetic acid and 4-hydroxy–3-methoxyphenylacetic acid in the rat. Clin. chim. Acta 12, 335–339 (1965).
Worlledge, S.M., Carstairs, K.C., Dacie, J.V.: Autoimmune haemolytic anaemia associated with α-methyldopa therapy. Lancet ii, 135–139 (1966).
Wurtman, R.J., Choit, C., Rose, C.: The fate of C14-dihydroxyphenylalanine (C14-dopa) in the whole mouse. J. Pharmacol, exp. Ther. 174, 351–356 (1970a).
Wurtman, R.J., Larin, F.: A sensitive and specific isotopic assay for the estimation of tyrosine transaminase. Biochem. Pharmacol. 17, 817–818 (1968).
Wurtman, R.J., Rose, C.M., Matthysse, S., Stephenson, J., Baldessarini, R.: L-Dihydroxyphenyl-alanine: effect on S-adenosylmethionine in brain. Science 169, 395–397 (1970b).
Wycis, H.T., Cunningham, W., Kellett, G., Spiegel, E.A.: L-Dopa in the treatment of post-surgical Parkinson patients. J. Neurosurg. 32, 281–285 (1970).
Yahr, M.D.: Abnormal involuntary movements induced by dopa: clinical aspects. In: L-Dopa and Parkinsonism, pp. 101–108, edit. A. Barbeaij And F.H. Mcdowell. Philadelphia: Davis 1970a.
Yahr, M.D.: Psychiatric aspects of L-dopa treatment. In: L-Dopa and Parkinsonism, pp. 328–329, edit. A. Barbeaij And F.H. Mcdowell. Philadelphia: Davis 1970b.
Yahr, M.D.: Results of long-term administration of levodopa in parkinsonism. Proc. 4th Bel-Air Symposium, Geneva, 1970c, in the press.
Yahr, M.D., Duvoisin, R.C., Schear, M.J., Barrett, R.E., Hoehn, M.M.: Treatment of Parkinsonism with levodopa. Arch. Neurol. 21, 343–354 (1969).
Yamanaka, Y., Walsh, M.J., Davis, V.E.: Salsolinol, an alkaloid derivative of dopamine formed in vitro during alcohol metabolism. Nature (Lond.) 227, 1143–1144 (1970).
Yamori, Y., Lovenberg, W., Sjoerdsma, A.: Norepinephrine metabolism in brainstem of spontaneously hypertensive rats. Science 170, 544–546 (1970).
Yaryura-Tobias, J. A., Diamond, B., Merlis, S.: The action of L-dopa on schizophrenic patients. Curr. ther. Res. 12, 528–531 (1970).
Yeh, B.K., Mcnay, J.L., Goldberg, L.I.: Attenuation of dopamine renal and mesenteric vasodilation by haloperidol: evidence for a specific dopamine receptor. J. Pharmacol, exp. Ther. 168, 303–309 (1969).
Yoshida, H., Kanuke, K., Namba, J.: Properties of a carrier system to transport L-dopa into brain slices. Nature (Lond.) 198, 191–192 (1963).
Youdim, M. B.H., Bonham Carter, S., Sandler, M., Hanington, E., Wilkinson, M.: A conjugation defect in tyramine-sensitive migraine. Nature (Lond.) 230, 127–128 (1971).
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1972 Springer-Verlag Berlin · Heidelberg
About this chapter
Cite this chapter
Sandler, M. (1972). Catecholamine Synthesis and Metabolism in Man: Clinical Implications (With Special Reference to Parkinsonism). In: Blaschko, H., Muscholl, E. (eds) Catecholamines. Handbuch der experimentellen Pharmakologie / Handbook of Experimental Pharmacology, vol 33. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-65249-3_19
Download citation
DOI: https://doi.org/10.1007/978-3-642-65249-3_19
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-65251-6
Online ISBN: 978-3-642-65249-3
eBook Packages: Springer Book Archive